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 i 
ABSTRACT 
 Human Uncoupling Protein 2 (hUCP2) is one of five known human UCPs which are 
found in the inner mitochondrial membrane and have been shown to facilitate the 
translocation of protons from the intermembrane space to the mitochondrial matrix. The 
detailed physiological role of UCP2 proton transport, the mechanism by which it mediates 
this proton transport, as well as its structure has also yet to be elucidated. In order to help 
determine the topology of UCP2 embedded in the membrane as well as its mechanism of 
proton transport, the intrinsic fluorescence properties of the two tryptophan residues (Trp) 
present in its structure (W176 and W283) were used. To this end, three substitution 
mutants were created by site-directed mutagenesis using primer overlap-extension PCR; 
these were: W176Y, W283F and W176Y-W283F. The three mutant cDNAs then introduced 
into a membrane-targeted bacterial expression system from which they were then 
expressed in E. coli and purified via autoinduction and immobilized metal affinity 
chromatography (IMAC). Fluorescence and circular dichroism spectroscopy were then used 
to confirm that the mutants retained native-like conformations. Fluorescence quenching 
assays with acrylamide were performed to probe the topology of UCP2 embedded in the 
membrane via the differing accessibility of each Trp to the acrylamide quencher. The final 
stage of this project involved probing the effects of the Trp residues on the proton transport 
activity of UCP2 via a proton transport assay previously developed in our lab. 
Unfortunately, the presence of high background fluorescence, as seen in the W176Y-W283F 
fluorescence spectra with excitation at 295nm, either due to tryptophan containing-
proteinaceous contaminants in the sample, or the presence of a deprotonated tyrosine 
residue (tyrosinate) in the folded structure of UCP2, has made it impossible to draw any 
definitive conclusions from the intrinsic fluorescence assays. The results of the proton 
transport assay for the W176Y-W283F Trp mutant and wt UCP2 indicate a role for the 
conserved UCP Trp residues in the proton transport activity of the protein based on a 
26.7% reduction in the transport rate of the double mutant in comparison to the wt protein. 
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1 UNCOUPLING PROTEIN 2 
1.1 Cellular Energy Production in Mitochondria: Proton Motive Force, 
ATP Synthesis and Uncoupling 
In eukaryotic cells, mitochondria are analogous to a power plant in that they 
convert energy into a usable form which may then be used to do work. In the case of 
the mitochondria this energy is obtained from the oxidation of molecules derived 
from food, and converted to adenosine triphosphate (ATP) through a process 
known as oxidative phosphorylation and the work done includes, among many 
things, most anabolic cellular processes. These organelles are enclosed by an outer 
membrane, which serves mainly as a protective barrier, and also contain an inner 
membrane, which has tightly controlled permeability.  The inner mitochondrial 
membrane also has a high protein content and is a crucial component for the 
function of the organelle.  As mentioned above, the harnessing of chemical energy as 
ATP by mitochondria occurs mainly via oxidative phosphorylation, a process which 
involves the addition of a phosphate group to ADP to form ATP and is catalyzed the 
enzyme F1/F0 ATP synthase. The oxidative phosphorylation catalysed by F1/F0 ATP 
synthase is driven by the controlled dissipation of a proton gradient, which is 
generated across the mitochondrial inner membrane by the proton pumping activity 
of complexes I, III and IV of the electron transport chain (ETC). More specifically, 
oxidation of nutrient molecules obtained from food intake leads to the reduction of 
  2 
the electron carriers NAD+ and FAD to NADH and FADH2, respectively. The reduced 
electron carriers, NADH and FADH2, then pass their electrons on to complexes I and 
II, respectively, of the ETC which are then passed down the ETC to complex IV 
where the electrons are then involved in the synthesis of water and via the catalytic 
reduction of molecular oxygen. As was mentioned, this electron transfer down the 
ETC leads to the translocation of protons from the mitochondrial matrix to the 
intermembrane space via the proton pumping activity of complexes I, III and IV, that 
in turn leads to the generation of both an electrical and chemical potential across 
the membrane, which together are commonly referred to as the proton motive 
force. It is this proton motive force that then drives the catalytic activity of F1/F0 
ATP synthase, which occurs via the passage of protons back through the F0 domain 
which in turn drives the rotation and resulting conformational change in the F1 
domain that causes the addition of inorganic phosphate (Pi) to ADP to form ATP 
(figure 1) [1].  
 It has been observed, that the proton motive force that is generated as a 
result of substrate oxidation in the mitochondria is not completely coupled to 
oxidative phosphorylation by F1/F0 ATP synthase and it has been found that 
coupling efficiency is as low as 50-65% in isolated rat skeletal muscle and 25-30% 
in cultured human β-cells and up to 25% of the basal metabolic rate of rates may be 
due to the futile cycling of protons between the intermembrane space and the 
matrix[2-5]. Moreover, it has also been observed that the coupling efficiency 
decreases exponentially as the proton motive force increases [5]. This proton leak, 
which uncouples the oxidation of food derived substrates from oxidative 
  3 
phosphorlyation has been shown to be mediated through the activity of various 
members of the mitochondrial anion carrier family of proteins, which are expressed 
in the inner mitochondrial membrane and which, as their name suggests, facilitate 
the transport of various anions across this membrane. Some examples of such 
proteins include: the adenine nucleotide translocase (ANT), mitochondrial 
phosphate carrier protein (SLC25A3), glutamate aspartate transporter (GLAST or 
SLC1A3), and uncoupling proteins (UCPs) [5,6,7].  As of yet, the physiological role of 
this anion carrier protein mediated uncoupling is not well established, with the 
exception being the case of uncoupling protein 1 (UCP1), whose uncoupling activity 
plays a well-established role in the process of non-shivering thermogenesis in the 
brown adipose tissue (BAT) of mammals [5]. Other less conclusively confirmed 
roles for the uncoupling of the mitochondrial proton from ATP synthesis via 
oxidative phosphorylation that have been proposed are the attenuation of 
mitochondrial reactive oxygen species (ROS) production, protection from obesity, 
regulation of fatty acid metabolism, regulation of insulin secretion by pancreatic β-
cells, nutrient sensing and metabolic regulation in the brain as well as adaptive 
thermoregulation [8]. 
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Figure 1: General Representation of Energy Harnessing by Mitochondria: A diagram 
depicting a general view of energy production in the mitochondria and how UCPs uncouples 
substrate oxidation from energy production. In general: the oxidation of substrate 
molecules obtained from food leads to the reduction of electron carriers, which in turn 
reduce complexes within the electron transport chain. These complexes then pass the 
electrons on through a total of 4 complexes, which leads to the production of an 
electrochemical gradient by the pumping of protons across the intermembrane space by 
complexes I, III and IV. The electrochemical gradient is then used to drive ATP synthesis by 
F1/F0 ATP synthase or alternatively, the electrochemical gradient can be dissipated by UCPs 
in a manner that does not produce ATP [23]. 
1.2 The Mitochondrial Uncoupling Proteins 
 In humans and most other mammals there are 5 known UCP homologues 
that are expressed, named UCP1-5, in order of discovery. UCP1, by virtue of its 
exceptionally high expression levels in BAT and consequently its discovery 19 years 
prior to the discovery of the second UCP, UCP2, (in 1978 and 1997, respectively) is 
the most extensively characterised UCP and serves as the archetype for 
investigating the catalytic mechanisms and functions of the other UCP homologues 
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and these properties will be discussed in detail below [8,9]. Currently there are no 
high resolution crystal structures available for any of the 5 UCP homologues, 
although a speculative model based on molecular modelling and comparison with 
the crystal structure of ANT, which is in the same family of proteins as the UCPs, 
proposes that the three dimensional structures of the UCPs share a very similar 
tripartite folding motif with ANT [11,12](see figures 2 and 3). This tripartite folding 
motif consists of 3 pseudo-repeats, each containing two transmembrane α-helices 
connected by loop regions, which, along with the amine and carboxy termini, are 
oriented towards the intermembrane space [11]. This putative model for the 
structure of the UCPs has been supported by the work of Berardi et al. which used 
the technique of nuclear magnetic resonance (NMR) fragment searching to probe 
the structure of UCP2 and confirmed that the structure of UCP2 shares the same 
overall folding motif as ANT (figures 2 and 3) [13]. 
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Figure 2: Comparison of Bovine ANT1 to Predicted Structure of UCP2 from Molecular 
Modelling: The proposed model of human UCP1 based on comparison to the structure of 
the bovine ANT using the MODELLER molecular modelling program showing side and top 
views (top and bottom, respectively) [11].  
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Figure 3: Comparison of Bovine ANT1 to Predicted Structure of UCP2 from NMR 
Fragment Searching: (A) The membrane topology of the primary sequence of UCP2, based 
on NMR fragment searching, the two tryptophan residues (W) present in UCP2 are 
highlighted with orange squares and the three arginine residues involved in nucleotide 
binding are highlighted with yellow circles [13]. (B) A comparison of the proposed model of 
UCP2 with ANT1 from the matrix side, showing overall similar structures with the most 
striking differences occurring in the thirds pseudo repeat (pink) [13]. 
 
1.2.1 Uncoupling Protein 1 – The Archetypal Uncoupling Protein 
 UCP1 is a 33 kDa protein that is expressed at high levels in the mitochondria of the 
BAT found in mammals, which is primarily involved in the maintenance of body 
temperature in response to cold through a process known as non-shivering thermogenesis 
[8,9]. The primary role of UCP1 in mediating this non-shivering thermogenesis occurs 
through the direct mediation of proton leak in the mitochondria, as well as certain other 
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aspects of its activity, such as: transport of certain anions, including Cl-, and fatty acid 
anions; activation by free fatty acids (FFAs); and inhibition by purine di- and tri-nucleotides 
(ADP, ATP, GDP and GTP), have been well established [8-11]. The thermogenic activity of 
UCP1 arises from its ability to catalyse the leak of protons across the inner mitochondrial 
membrane, from the intermembrane space to the matrix, in a manner that does not drive 
oxidative phosphorylation and instead releases some of the energy stored in the 
mitochondrial proton gradient as heat, in response to activation by FFAs, through a β-
adrenergic receptor mediated pathway [8]. Despite the fact that UCP1’s ability to facilitate 
proton leak in the mitochondria is so well established, the exact mechanism of this leak, to 
date, remains elusive for UCP1 and all of its homologues. Due to its well characterised 
activity, in addition to its clearly demonstrated physiological role in BAT, UCP1 serves as a 
useful archetype in the study of the rest of the UCP homologues. 
1.2.2 Uncoupling Protein Homologues – UCP2-5 
 The uncoupling protein homologues UCP2-5 have been identified more recently, 
starting with the discovery of UCP2 in 1997, followed by UCP3 later in 1997, UCP4 in 1999 
and UCP5, which was discovered in 1998 as brain mitochondrial carrier protein-1 (BMCP1) 
but not identified as a member of the uncoupling protein family until after the discovery of 
UCP4 [9, 14-18]. Since their discovery, it has been confirmed that these UCP homologues 
share many of the characteristic features of UCP1, such as transport of protons from the 
intermembrane space, activation by FFAs, and inhibition of the aforementioned proton 
conductance in the presence of purine di- and tri-nucleotides [8]. However, in contrast with 
UCP1, while several physiological roles have been proposed for the uncoupling protein 
homologues, as of yet none of these is definitively established. A common feature of most of 
the proposed roles for the uncoupling protein homologues is that they involve the 
protection of the cells they are expressed in from the production and harmful downstream 
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effects of ROS. This proposed ability of the UCP homologues to attenuate the production 
would seem logical given the observations that: 1) mitochondria are the main site of ROS 
production in the cell, with superoxide being produced as a result of the escape of electrons 
from complexes I and III of the ETC; 2) even slight increases in the mitochondrial 
membrane potential lead to substantial rises in ROS production 3) UCPs, through their 
capacity to dissipate the mitochondrial membrane potential, have the potential to 
ameliorate this increase in ROS production and 4) in the case of UCP2 and UCP3, there is 
strong experimental evidence for their activation by superoxide radicals, as well as 
downstream ROS, such as 4-hydroxy-2-nonenal (HNE) and carbon centred lipid radicals [8, 
19-22]. 
1.2.3 The Proposed Mechanisms of Proton Transport by Uncoupling Proteins 
 The mechanism by which the UCPs mediate their proton and anion transport 
activities is still the subject of much debate. At present, there are two main models 
for the mechanism of UCP-mediated proton conductance that have been proposed, 
each with several pieces of supporting evidence [23-28]. The fatty acid buffering 
hypothesis posits that UCP-mediated proton leak occurs via the protonation of fatty 
acid anions in the outer leaflet of the mitochondrial inner membrane, followed by 
their subsequent translocation to the inner leaflet via a flip-flop mechanism, 
deprotonation in the matrix, due to the change in pH across the membrane, and 
finally, export of the resulting fatty acid anions by the UCPs through an, as yet 
undetermined mechanism (figure 4B) [23, 26]. Alternatively, the fatty acid cofactor 
model proposes that the proton leak via the UCPs occurs through a mechanism in 
which the carboxyl groups on FFAs act as buffering cofactors in conjunction with 
proton conducting residues, such as the carboxylate groups of aspartate residues 
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(figure 4A) [23, 26]. However, recent evidence has called into question the validity 
of the fatty acid buffering hypothesis, in addition to certain aspects of the fatty acid 
cofactor model these include: the observation that UCP1-mediated respiratory 
uncoupling is activated by undecanesulfonate (C11S), despite the fact that the 
anionic group on C11S is highly acidic and therefore unable to accept a proton at 
physiologically relevant pHs and also, has been shown to be incapable of flip-flop 
between membrane leaflets; as well as observations from molecular modeling 
studies, which suggest that UCPs function in a channel like manner based on the 
presence of a funnel-like central pore that contains the nucleotide binding site in 
addition to two conserved, symmetrical salt bridges which could help facilitate 
substrate transport [27-29].  
 
Figure 4: Diagram Representing Two of the Proposed Mechanisms for Proton 
Transport: (A) A diagram of the fatty acid cofactor model of proton transport by UCPs. In 
this model the fatty acids act as cofactors which provide additional carboxyl groups that 
accept protons from the intermembrane space and pass them on to proton buffering amino 
acids (R-COO-) leading to translocation of protons into the matrix [23].  (B) A diagram 
depicting the fatty acid buffering model of proton transport by UCPs. In this model UCPs 
transport fatty acid anions from the matrix to the intermembrane space where they 
protonate, flip back to matrix side through a flip-flop mechanism and deprotonate into the 
matrix [23]. 
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1.2.4 Uncoupling Protein 2 
 The second UCP that was identified, UCP2, has the widest tissue distribution 
of any of the UCP homologues, with near ubiquitous expression of its mRNA in 
mammals [9]. The wide tissue distribution of UCP2 mRNA expression has made it a 
particularly attractive target for research and has led to the observation that UCP2 
may play a role in the pathological mechanisms of conditions such as chronic 
inflammatory diseases, obesity and type 2 diabetes [14,23,30-36]. Interestingly, 
despite its ubiquitous mRNA expression, the tissues in which detectable levels of 
UCP2 protein have been found are far more limited, suggesting that regulation of 
UCP2 expression may occur at both the transcriptional and translational levels 
[37,38]. For example, although the UCP2 mRNA is transcribed at high levels in 
spleen, heart, pancreatic β-cell, thymus, lung, macrophage, BAT and white adipose 
tissue, and in lower quantities in the brain, kidneys, liver and skeletal muscle, in 
tissue samples of BAT, skeletal muscle and heart no UCP2 protein could be detected 
[23,37]. In addition to its proposed role in several diseases, along with its 
widespread tissue distribution, UCP2 is also an attractive target for study, and will 
be the focus of the proposed work, because it has the highest sequence homology 
with UCP1 (59%) of any of the UCPs and should therefore share many of its 
previously determined structural and functional properties; it also has two highly 
conserved Trp residues, which are present in all 5 of the uncoupling protein 
homologues and whose usefulness as probes of protein structure and function will 
be the focal point of the next chapter (see figures 5 and 6) [28].  
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1.3 Research Objectives 
Based on the properties of UCP2 outlined in the introductory chapter, the following 
research goals were planned for this study.  
 The first goal of the research project was to develop an expression system for 
efficient expression of UCP2 in bacterial membranes. This objective was achieved 
through removal of an endogenous NcoI restriction site from the cDNA sequence of 
UCP2 by silent mutation to allow for its introduction into an expression vector that 
was designed to express the protein in the bacterial cell membrane. The resulting 
plasmid with the wt UCP2 cDNA was then transformed into E.coli cells.  
 The second goal was to study the overall conformation and topology of UCP2 
in membranes using biophysical spectroscopic techniques. To achieve this objective 
the only two Trp residues in UCP2, W178 and W283, were targetted. Overall, three 
Trp mutants of UCP2 cDNA were prepared, using the technique of overlap extension 
PCR. Two of these proteins were single mutants in which Trp was replaced by other 
aromatic residues, Phe or Tyr. The third protein was a double mutant version of 
UCP2 where the two Trp residues were replaced by Phe and Tyr. The resulting 
mutant cDNAs were introduced into the membrane-targeted expression vector and 
transformed into E.coli cells. Overexpressed wt UCP2 and the selective Trp mutants 
of UCP2, were then isolated, purified and verified by gel electrophoretic analytical 
techniques. The next step of this objective was to confirm that the selective Trp 
mutants of UCP2 retained native-like conformation using far-UV Circular Dichroism 
(CD) spectroscopy. The final step was to explore the local environment ot the Trps 
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in UCP2. For this purpose, fluorescence properties of Trp in wt UCP2 and each of its 
selective Trp mutants was characterized.   
Several types of fluorescence assays were performed to complete the overall 
objective of the project, which was to examine the role of the conserved Trp 
residues that are present in all UCPs on their structure and proton transport 
activity, as well as to explore the overall membrane topology of UCP2 and the 
membrane topology of the nucleotide binding site of UCP2. These fluorescence 
based assays included SDS denaturation, acrylamide quenching, and proton 
transport assays.  
The expected results, based on the limited structural information available 
for UCP2, were that the W176 residue would be found to be closer to the membrane 
interface than W283 residue, and the W283 residue was expected to be closer to the 
nucleotide binding site than the W176 residue. The Trp residues were not expected 
to directly play a role in proton transport by UCP2, but were expected to play some 
role in maintaining the native conformation of the protein. The introduced aromatic 
residue mutations were chosen to minimise change to the overall structure, and any 
changes in the conformation were expected to be in the local environment around 
each residue. This implies that despite similarity in overall conformation of the wt 
protein and its mutants, there may still be substantial differences in the proton 
transport activity of the proteins. Finally, it is expected that the selective Trp mutant 
with both Trp residues knocked out will have little to no fluorescence signal relative 
to the other UCP2 mutants and the wt protein. The details of the objectives of and 
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the techniques used in this study will be explained and discussed in the following 
chapters.  
 
Figure 5: Model of UCP2 from NMR Fragment Searching with Trp Residues Visualised: 
A view of the model of the structure of UCP2, which has been proposed based on NMR 
fragment searching, with the tryptophan residues visualised in red and the arginine 
residues involved in nucleotide binding visualised in blue (W283) and orange (W176) [39]. 
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Figure 6: Sequence Alignment for the UCPs with ANT1: Sequence alignment of the 
human UCPs and bovine ANT1 based on the EBI Clustal W2 Multiple Sequence Alignment 
Tool and Swiss-Prot entries hUCP1 (P25874), hUCP2 (P558519), hUCP3 (P55916), hUCP4 
(O95847), hUCP5 (O95258), and ANT1 (P02722) [41]. The positions of the two tryptophan 
residues are highlighted in yellow, the positions of the arginine residues involved in 
nucleotide binding are highlighted in red, transmembrane helices forming regions, as 
predicted by hydrophobicity scales are highlighted in green, the amphipathic helices of 
ANT1 are shown in grey and the known transmembrane helices of ANT1 are shown in 
magenta with the corresponding regions in UCP1 highlighted in light blue [40]. 
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2 BIOPHYSICAL AND MOLECULAR BIOLOGY TECHNIQUES 
FOR STUDYING STRUCTURE AND FUNCTION OF 
MEMBRANE PROTEINS 
2.1 The Use of Selective Trp Mutants of Membrane Proteins to Examine 
Folding, Membrane Topology and Enzymatic Activity 
 
2.1.1 Site-Directed Mutagenesis by Overlap Extension PCR 
In order to produce selective Trp mutants of UCP2, site-directed mutagenesis 
by primer overlap extension PCR was performed [43, 44]. This method of site-
directed mutagenesis involves the introduction of a desired mutation into a gene of 
interest via three rounds of PCR with different combinations of four primers 
(outlined in figure 7). These four primers consist of: a forward flanking primer 
(primer A), which simply consists of the first ~15 base pairs of the sense strand of 
the gene of interest; a reverse primer (primer D), which is the reverse compliment 
to the 3’ end of the sense strand and therefore simply copies the last ~15 base pairs 
of the antisense strand; the two remaining primers (Primers B and C) form a 
complementary pair approximately centred on the mutation one wishes to 
incorporate, if the mutation one wishes to incorporate is an addition or substitution 
these primers will simply consist of the added or swapped base pairs flanked by 
~15 base pairs of the gene of interest’s sense strand (primer B) or antisense strand 
(primer C) on both sides of where the desired mutation is to be incorporated. Once 
primers are designed and ordered, producing the gene of interest simply consists of 
three rounds of PCR as follows: round 1 with the original gene of interest as the 
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template and primers A and B as the forward and reverse primers, respectively; 
round 2 with the original gene of interest as the template and primers C and D as the 
forward and reverse primers, respectively; and a third round with the purified 
products of rounds 1 and 2 used as the template and primers A and D as the forward 
and reverse primers, respectively, yielding the gene of interest with the desired 
mutation added.  
 
Figure 7: A Schematic Representation of Site-Directed Mutagenesis by Primer Overlap 
Extension PCR: A visual representation of the technique of site directed mutagenesis by 
primer overlap-extension PCR [44]. 
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2.1.2 Examination of Protein Secondary Structure by Far-UV Circular Dichroism 
Spectroscopy 
Plane polarised light can be thought of as being comprised of two circularly 
polarised components with equal magnitude. CD spectroscopy is based on the 
principle that when these circularly polarised components interact with a chiral 
molecule, the left handed and right handed components will be differentially 
absorbed, resulting in elliptical polarisation and as such data is usually reported in 
degrees of molar elipticity (see figure 8) [45].  When studying the secondary 
structure of proteins with CD spectroscopy, circularly polarised light in the 170-
260nm region of the far-UV spectrum is typically used, in this region the primary 
chromophores are the amide bonds of the peptide backbone [45]. In secondary 
structure elements such as α-helices and β-sheets, the peptide chromophores are 
arranged in a very ordered way. The different orientations of the peptide bond 
chromophores in the various different types of secondary structure, result in shifts 
in the wavelengths that the chromophores absorb at, as well as changes in the 
intensity of absorption. Therefore, the CD spectra for each type of secondary 
structure is characteristic of that particular element and CD spectroscopy can be 
used to estimate the overall secondary structure composition of a protein (see 
figure 9)[46]. 
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Figure 8: Depiction of Circular Dichroism: An illustration of the origin of elipticity arising 
from the differential absorption of left and right handed circularly polarised, also known as 
circular dichroism [46]. 
 
 
Figure 9: CD Spectra of Different Secondary Structure Elements: The Far UV CD spectra 
characteristic of various types of secondary structure. With the solid line sowing an, α-helix; 
the long dashed line an anti-parallel β-sheet; the dotted line a type I β-turn; the cross 
dashed line, an extended 31-helix or polyproline II helix; and the short dashed line, a 
disordered structure [46]. 
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2.1.3 Fluorescence Based Spectroscopic Techniques for the Study of Proteins 
One technique for probing the structure and function of proteins is fluorescence 
spectroscopy. One method of applying fluorescence spectroscopy to the study of 
proteins, involves taking advantage of the intrinsic fluorescence properties of the 
aromatic amino acids, namely tryptophan, tyrosine and phenylalanine. Of these 
amino acids, tryptophan is the fluorophore most commonly used in fluorescence 
spectroscopy, due the fact that it can be selectively excited and due to the sensitivity 
of its fluorescence to the polarity of the local environment around the residue [41]. 
Trp residues can be excited by UV light at 295nm, a wavelength at which the 
absorbance and resulting excitation of phenylalanine and tyrosine residues are 
insignificant. Trp residues that are excited at 295nm when fully exposed to a polar 
environment, such as water, have a resulting peak emission at around 350nm [41]. 
In contrast, due to the highly sensitive nature of the fluorescence of the residues to 
the polarity of their environment, a Trp residue that is excited at 295nm but is 
completely inaccessible to a polar solvent, such as a residue buried in the 
hydrophobic core of the protein or the membrane embedded domain of an integral 
membrane protein, will have a resulting peak emission that is blue-shifted down to 
around 300nm and a more structured emission spectrum, in that the slight shoulder 
present in the longer wavelengths of the absorption spectrum of tryptophan will 
become apparent in the emission spectrum [41]. Therefore, due to the selective and 
sensitive nature of Trp fluorescence, changes in the emission spectra of a protein 
that is excited at 295nm in response to, for instance, the addition of a possible 
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ligand, can be used to make inferences about properties of the protein, such as 
conformational changes in response to binding or the mechanism of action [41].  
 Fluorescence quenching is a widely applied technique that is used to assess 
the accessibility of a fluorophore (Trp), to a quenching agent [41]. There are two 
main types of quenching, static and dynamic. In static quenching, the quenching of 
fluorescence occurs via the formation of a complex between the fluorophore and the 
quenching agent in the ground state. In contrast, dynamic quenching occurs through 
the transfer of energy from an excited state fluorophore to a quenching agent 
through several different mechanisms, with the most relevant to the study of 
proteins being direct collisional energy transfer [41,42]. As the name suggests, 
collisional energy transfer involves the transfer of energy through direct collisions 
between the excited state fluorophore and the quenching agent resulting in a 
relaxation of the excited state of the fluorophore without the emission of photons 
[42]. The quenching agents commonly used for collisional quenching mostly consist 
of small, polar molecules such as acrylamide, iodide and molecular oxygen [42]. Site-
directed mutagenesis to produce selective tryptophan mutants of a protein is a 
method that is sometimes used to compliment the study of proteins via their 
intrinsic fluorescence and fluorescence quenching, by allowing the local 
environment of each individual Trp residue in a given protein, to be probed 
separately, which removes the need for trying to assign specific aspects of changes 
in the spectra to certain Trp residues [41]. 
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2.1.3.1 Spectral Properties of Proteogenic Amino Acids 
Phenylalanine, tyrosine and tryptophan are the three aromatic amino acids 
found in proteins. All three of these aromatic amino acids possess the ability to act 
as intrinsic fluorophores within proteins. Of the three, Phe has the weakest 
fluorescence by a large margin, followed by Tyr which had moderate fluorescence 
and finally Trp, which the highest quantum yield relative to the other aromatic 
amino acids [39]. Figure 10 shows the general absorption and emission spectra for 
each of the three aromatic amino acids found in proteins, from this it can be seen 
that Trp residues have an absorption spectrum that extends to just past 300nm and 
that at 295nm Trp still has significant absorbance, whereas Phe and Tyr do not.  The 
presence of this range of wavelengths, where Trp residues absorb photons and the 
other aromatic residues do not, means that the fluorescence of Trp residues can be 
selectively excited at these wavelengths without appreciable fluorescence from Tyr 
or Phe residues [41]. Another interesting property of Trp residues is that they are 
highly sensitive to the polarity and pH of the local environment around the residues 
with a significant blue shift coupled with an increase in fluorescence intensity when 
in a nonpolar versus a polar environment, respectively. This sensitivity to the 
environment around the Trp residues is not seen in the other aromatic amino acids, 
which are fairly insensitive to changes in their local environments [41]. 
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Figure 10: Absorbance and Emission Spectra of the Aromatic Amino Acids: The general 
absorption and emission spectra for each of the three aromatic amino acids found in 
proteins. The spectra on the left in (red) show the absorbance profiles of the amino acids 
and the spectra on the right (purple) show the emission profiles of each amino acid. Figure 
was retrieved from [41]. 
 
2.1.3.2 Intrinsic Fluorescence of Trp Containing Proteins 
 The sensitivity of Trp fluorescence to the environment surrounding the 
residue, as well as the fact that Trp residues can be selectively excited at 295nm, as 
discussed above, give rise to the possibility of using the residue as a fluorescent 
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probe of structure. This application is especially useful for studying membrane 
proteins, for which structural information is usually difficult to obtain by other 
methods such as X-ray crystallography [41,47.] As a logical extension of the 
aforementioned fluorescence properties, the wavelength of emission, as well as the 
quantum yield of fluorescence, can give information about the relative position of a 
Trp residue in a protein that is folded in a membrane, with membrane buried Trp 
residues having lower wavelengths of emission (blue-shifted) and higher quantum 
yields relative to those of solvent exposed Trp residues. Therefore fluorescence 
spectroscopy of proteins with excitation at 295nm can yield information about the 
overall topology of integral membrane proteins, especially when applied to selective 
Trp mutants, which contain only a single Trp residue, thus allowing the fluorescence 
signal obtained to be related solely to that residue [41, 42]. 
2.1.3.3 Quenching of Trp Fluorescence 
 Fluorescence quenching is a widely used technique that has been in use since 
the 1960s. The technique is used to determine the accessibility of fluorophores, such 
as Trp in proteins, to a quenching agent [42, 48].  These quenching agents are 
usually polar molecules or ions dissolved in the solvent. As such, the fluorescence of 
Trp residues on the surface of a cytosolic protein and those at the membrane-
solvent interface of membrane proteins will experience the greatest degree of 
fluorescence quenching. Conversely, if the Trp residues are buried in the 
hydrophobic core of a protein, or embedded within the membrane, they have their 
fluorescence quenched to a lesser extent due to decreased accessibility to the 
quenching agent [42]. This can yield topological information on the protein being 
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studied as well as information on structural changes in response to ligand binding. 
Some common quenchers used in the study of biomolecules are shown in table 1 
[41]. 
Table 1: Assorted Quenchers and their Corresponding Fluorophores: Common 
quenchers used for fluorescence quenching studies and the fluorophore they quench. Table 
was obtained from [41]. 
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3 MATERIALS, EXPERIMENTAL DESIGN AND METHODS 
3.1 Materials 
 Primers were ordered from Life Technologies, a Thermo Fisher Subsidiary 
(Massachusetts, USA); the Wizard Plus SV Miniprep DNA Purification System and 
Wizard SV Gel and PCR Clean-Up System were from Promega (Wisconsin, USA.); 
HotStar HiFidelity DNA polymerase kit was from Qiagen (Germany); DNA 
sequencing was performed at The Centre For Applied Genomics (TCAG) (Ontario, 
Canada). All other chemicals used for the PCR and subsequent cloning into 
pET26b(+) and transformation into E.coli were order from either BioShop Canada 
Inc. (Ontario, Canada) or Thermo Fisher (Massachusetts, USA). 
 n-Octyl-β-D-Glucopyranoside (OG) was obtained from Anatrace (California, 
USA); Nickel-NTA beads were obtained from Qiagen (Germany); 
Tris(hydroxypropyl)phosphine (THP) was obtained from EMD Milipore 
(Massachusetts, USA); acrylamide monomer (no bis-acrylamide) was obtained in 
powder from BioShop Canada Inc. (Ontario, Canada); L-α-Lecithin, composed of a 
minimum 60% phosphatidylcholine with the other 40% primarily comprised of 
phosphatidylethanolamine with small amounts of cholesterol and triglycerides, was 
obtained from Sigma-Aldrich (Missouri, USA); SPQ fluorophore was obtained from 
Biotium Inc. (California, USA); ATP and sodium palmitate were also purchased from 
Sigma-Aldrich (Missouri, USA); SM-2 Biobeads were obtained from Bio-Rad 
(California, USA); Sephadex G25-300 (Coarse) were obtained from GE Healthcare 
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(United Kingdom). Valinomycin and Nigericin were purchased from Sigma-Aldrich 
(Missouri, USA) and stored in 100% ethanol at -40°C; all centrifugation took place in 
Beckman-Coulter (California, USA) rotors and centrifuges unless otherwise noted. 
All other chemicals used in the fluorescence assays of UCP2 were either purchased 
from BioShop Canada Inc. (Ontario, Canada) or VWR (Pennsylvania, USA). 
3.2 Experimental Design and Methods 
3.2.1 Site-Directed Mutagenesis by Primer Overlap Extension PCR and Cloning into 
the Bacterial Membrane-Targeting pET26b(+) Vector 
The first objective of this project was to clone N-terminally His-tagged wt 
UCP2 into the pET26b(+) vector. In order to accomplish this, N-terminally His-
tagged wt UCP2-pET21d was used as a template, and two gene flanking primers 
were designed for site-directed mutagenesis by overlap-extension PCR by choosing 
a sequence, ~30bp long, on opposite strands at either end of the wild type (wt) 
hUCP2 gene, with the forward flanking primer containing the His-tag sequence as 
well as an NcoI site at the 5’ end and the reverse primer containing a HindIII 
restriction site downstream of the coding sequence (see appendix 1 for a full list of 
the primers used). A pair of mutagenic primers was also designed to introduce a 
single base pair change in order to knock out an endogenous NcoI site in UCP2 
without altering the translated sequence. This was accomplished by copying ~15 
nucleotides from either side of the endogenous NcoI site and knocking it out by 
changing the CCATGG recognition site to CTATGG.  wt UCP2-pET21 in DH5α E.coli 
was used to inoculate a 10mL stock of Luria-Bertani (L.B.) broth containing 
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50µg/mL of ampicillin in a 15mL falcon tube. The inoculated culture was then 
loosely capped and grown at 37°C with 240 RPM of horizontal shaking in a shaking 
incubator for 18h. The cells were subsequently spun down in a clinical centrifuge at 
4000xg for 10 minutes and plasmid was isolated using the Wizard Plus SV Miniprep 
DNA Purification System  (Promega), according to the available protocol and then 
used as a template for amplification and mutagenesis to yield the desired Trp 
mutations [49]. To produce the N-terminally His-tagged UCP2 with the endogenous 
NcoI site knocked out and with the 5’NcoI site added, the NcoI knockout mutagenic 
primer set was used, and primer overlap extension PCR was performed. All PCR was 
performed using the HotStar HiFidelity Polymerase Kit (Qiagen) and all reactions 
were set up in dome capped PCR tubes as outlined in table 2. The PCR tubes were 
subsequently placed in a thermocycler and cycled using the conditions outlined in 
table 3. The resulting PCR products were then run on a 1% agarose gel at 120V for 1 
hour with a 1kb ladder and imaged using the VersaDoc 4000 Gel Imaging System 
(Bio-Rad) in order to confirm that DNA bands of the expected length were produced. 
Following confirmation of the presence of PCR products of the expected lengths for 
the first two rounds of PCR, a third round of PCR was performed yielding  the ~1kb 
N-terminally His-tagged UCP2 with a 5’NcoI restriction site added and the 
endogenous UCP2 NcoI site knocked out. 
Following the amplification and mutagenesis of UCP2, the next goal was to 
clone the wt UCP2 into the pET26b(+) expression vector, which contains a pelB 
leader sequence that allows for targeting of an expressed gene product to the 
bacterial membrane. The UCP2 NcoI knockout produced by PCR was purified by gel 
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purification using the SV gel and PCR Cleanup kit (Promega) according to the kit 
protocol [50]. Next, 1.5µg of each PCR product and 1.5µg of empty pET26b(+) vector 
were subjected to a double restriction digest, with NcoI-HF and HindIII-HF from 
NEB, at 37°C for 3 hours in CutSmart Buffer (New England Biolabs). The products of 
the double digests were then gel purified as described above for the PCR products. 
Each of the mutant hUCP2 genes were then ligated into pET26b(+) vectors. The 
ligation reactions consisted of 50ng of the restriction digested pET26b(+) vector 
and ~200-300ng of a digested hUCP2 mutant gene, with 1μL T4 DNA ligase. The 
ligation reactions were incubated at 16⁰C for 14h. The UCP2-pET26b(+)was then 
used to transform DH5α and BL21 (DE3) RIPL E.coli cells (hereafter referred to as 
BL21 CD+), as described in the following section. 
Two additional sets of mutagenic primers were subsequently designed with 
the aim of producing three selective Trp mutants of UCP2 in a pET26b(+) expression 
vector (W176Y, W283F and W176Y-W283F), using the newly produced wt UCP2-
pET26b(+) construct as a template. This was achieved by again using primer 
overlap-extension PCR with same flanking primers used for amplifying wt UCP2 
from the pET21d vector.  Four additional primers were designed to introduce the 
desired mutations into the hUCP2 gene. These primers consisted of two 
complementary pairs, one to introduce the W176Y mutation and the other to 
introduce the W283F mutation. The primers for the W176Y mutation were designed 
by copying a ~15bp sequence on both sides of the Trp codon at position 176, for the 
sense strand primer (primer C1) the TGG Trp codon was replaced with a TAC Tyr 
codon and for the antisense strand primer (primer B1) the CCA bases were replaced 
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with GTA. The primers for the W283F mutation were designed by again copying a 
~15bp sequence on both sides of the trp codon, this time at position 283, for the 
sense strand primer (primer C2) the TGG Trp codon was replaced with a TTC Phe 
codon and for the antisense strand primer (primer B2) the CCA bases were replaced 
with TTC. To introduce the W176Y-W283F mutation into the hUCP2 gene both the 
W176Y primers and the W283F primers will be used as described below (see 
appendix 1 for a full list of the primers used). 
wt UCP2-pET26b(+) plasmid was isolated used as a template for amplification 
and mutagenesis to yield the desired Trp mutations [49]. To produce the W176Y 
and W283F mutations, mutagenic primer sets 1 and 2 were used, respectively, and 
primer overlap extension PCR was performed. All PCR was performed using the 
HotStar HiFidelity Polymerase Kit (Qiagen) and all reactions were set up in dome 
capped PCR tubes as outlined in table 4 [51]. The PCR tubes were subsequently 
placed in a thermocycler and cycled using the conditions outlined in table 3. The 
resulting PCR products were then run on a 1% agarose gel at 120V for 1 hour with a 
1kb ladder and imaged using the Bio-Rad VersaDoc 4000 Gel Imaging System in 
order to confirm that of DNA bands of the expected length were produced. 
Following confirmation of the presence of PCR products of the expected lengths for 
the first two rounds of PCR, a third round of PCR was performed yielding each of the 
~1kb single Trp mutants (W176Y and W283F). In order to produce the double Trp 
mutant (W176Y-W283F) the W176Y product was then gel purified, as described 
above, and then used as a template for the first two rounds of primer-overlap 
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extension PCR with the W283F primers, and cycled under the conditions outlined in 
table 3. 
 Following the amplification and mutagenesis of UCP2, the next goal was to 
clone the UCP2 Trp mutants into the pET26b(+) expression vector. In order to clone 
the desired UCP2 inserts into the pET26b(+) vector, a glycerol stock of empty 
pET26b(+) vector in DH5α E.coli was used to grow up a 10mL as described 
previously for UCP2-pET21 but with the ampicillin replaced by 50µg/mL of 
kanamycin (kan). Plasmid was again isolated from the overnight culture using the 
Wizard Plus SV Miniprep DNA Purification system (Promega) [49]. After isolating 
the plasmid the UCP2 Trp mutant genes produced by PCR were purified by gel 
purification using the Promega SV gel and PCR Cleanup kit according to the kit 
protocol [50]. The 1.5µg of each PCR product and 1.5µg of empty pET26b(+) vector 
were then subjected to a double restriction digest, with NcoI-HF and HindIII-HF from 
NEB, at 37°C for 3 hours in CutSmart Buffer. The products of the double digests 
were then gel purified as described above for the PCR products. Each of the mutant 
hUCP2 genes were then ligated into pET26b(+) vectors. The ligation reactions 
consisted of 50ng of the restriction digested pET26b(+) vector and ~200-300ng of a 
digested hUCP2 mutant gene, with 1μL T4 DNA ligase. The ligation reactions were 
incubated at 16⁰C for 14h. 
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Table 2: PCR Reaction Setup for NcoI Knockout/Addition for wt UCP2: Volumes of each 
component for overlap-extension PCR reactions used to produce UCP2 with its endogenous 
NcoI restriction site removed by the silent mutation of a single nucleotide and an NcoI 
restriction site added immediately adjacent to the gene on the 5’ end, as well as a HindIII 
site on the 3’ end. 
 
PCR Rounds 1 and 2 
(Single Mutants) 
PCR Round 3 
5X HotStar HiFidelity 
PCR Buffer 
10µL 10µL 
HotStar HiFidelity DNA 
Polymerase 
1µL 1µL 
Forward Primer 
(100µM in H2O) 
0.5µL 0.5µL 
Reverse Primer 
(100µM in H2O) 
0.5µL 0.5µL 
Template DNA 
(50-100ng/µL) 
1µL Isolated UCP2-pET21 
1µL Purified Round 1 PCR 
Product 
+ 
1µL Purified Round 2 PCR 
Product 
Nuclease Free H2O 37µL 37µL 
Total Reaction Volume 50µL 50µL 
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Table 3: Cycling Conditions Used for PCR Reactions: Thermocycler conditions used for 
all overlap-extension PCR reactions. 
Cycling Steps 
(Number of 
Cycles) 
 
PCR Rounds 
1 and 2 
PCR Round 3 
Activation 
(1X) 
Temperature 
(°C) 
95 95 
Time per cycle 
(s) 
300 
300 
 
Denaturation 
(40X) 
Temperature 
(°C) 
94 94 
Time per cycle 
(s) 
15 15 
Annealing 
(40X) 
Temperature 
(°C) 
59 59 
Time per cycle 
(s) 
30 30 
Extension 
(40X) 
Temperature 
(°C) 
72 72 
Time per cycle 
(s) 
30 60 
Final Extension 
(1X) 
Temperature 
(°C) 
72 72 
Time per cycle 
(s) 
600 600 
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Table 4:  PCR Reaction Setup for Site-Directed Mutagenesis of Trp Residues in UCP2: 
Volumes of each component for overlap-extension PCR reactions used to produce the three 
previously described selective Trp mutants of UCP2. 
 
PCR Rounds 1 and 2 
(Single Mutants) 
PCR Round 3 
5X HotStar HiFidelity PCR 
Buffer 
10µL 10µL 
HotStar HiFidelity DNA 
Polymerase 
1µL 1µL 
Forward Primer 
(100µM in H2O) 
0.5µL 0.5µL 
Reverse Primer 
(100µM in H2O) 
0.5µL 0.5µL 
Template DNA 
(50-100ng/µL) 
1µL Isolated UCP2-
pET26b(+) 
(W176Y and W283F) 
Or 
1µL W176Y-pET26b(+) 
(W176Y-W283F) 
1µL Purified Round 1 PCR 
Product 
+ 
1µL Purified Round 2 PCR 
Product 
Nuclease Free H2O 37µL 37µL 
Total Reaction Volume 50µL 50µL 
 
3.2.2 Transformation of DH5α and BL21 Codon Plus E.coli with hUCP2 Trp Mutants 
in pET26b(+) Vector 
 Each of the cloned UCP2 Trp mutant vectors was then used to transform 
chemically competent DH5α E.coli cells. This was done by adding ~100ng of vector 
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to 100μL aliquots of competent DH5α E.coli cells and then incubating on ice for 30 
min, which was then followed by heat shock at 42⁰C for 90s. After the heat shock the 
cells were placed back on ice for 30 min. The cell aliquots were diluted to 900μL 
with LB broth and incubated at 37⁰C for 1h. After this incubation, 100μL aliquots of 
the cultures were plated onto LB-Agar plates containing 50μg/mL of kan. These 
plates were inverted and incubated at 37⁰C overnight. 
 Following the overnight incubation, colonies were selected from the plates 
and the success of the transformation was evaluated by colony PCR. Colony PCR 
reactions were prepared with 1.8μL 10x thermo Pol buffer, 0.36μL 1mM 
deoxynucleotide triphosphate mixture, 0.5μL 100μM primer A, 0.5μL 100μM primer 
D, 0.09μL Taq DNA polymerase and 11.75μL nuclease free H2O. Each PCR reaction 
was then inoculated with one of the colonies selected from the agar plates used in 
the transformation reaction. The PCR reaction mixtures was then placed in a 
thermocycler, and cycled under the following conditions: 5 minutes at 95⁰C for the 
initial activation, followed by 30 repeats of the cycle 15s of denaturation at 94⁰C, 
30s of annealing at 58⁰C and 1 minute of extension at 72⁰C. The PCR reaction again 
ended with a final extension step of 10 minutes at 72⁰C. The results of the colony 
PCR were analysed by agarose gel electrophoresis on a 0.8% agarose gel, stained 
with ethidium bromide. 
Glycerol stocks were prepared for colonies confirmed to contain the mutant 
hUCP2 gene insert (1 for each mutation). This involved growing up 4mL overnight 
cultures, containing 50μg/mL Kan, for each colony that was selected. 0.7mL from 
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each culture was then mixed with 1.3mL 50% glycerol, in a 2mL tube and these 
were stored at -80⁰C until used. Plasmid isolation was performed on each of the 
mutants as described for pET26b(+) in the above section and samples of the 
plasmid were sent to The Centre for Applied Genomics (TCAG) (The Hospital for 
Sick Children, Toronto, ON) for DNA sequencing. All plasmid samples sent for 
sequencing had the sense and anti-sense strands of the insert region sequenced 
with a T7 promoter primer and a T7 terminator primer, respectively. 
 The isolated plasmid was then transformed into BL21 CD+, using the same 
procedure as was used for the DH5α transformation with the addition of 25µg/mL 
streptomycin (strep) and 25µg/mL of chloramphenicol (cam) to the selective agar 
plates. 
3.2.3 Membrane Targeted Expression of hUCP2 Mutants from BL21 Codon Plus 
 Following verification of the presence of the desired UCP2 inserts in 
pET26b(+) by DNA sequencing, recombinant wt UCP2, as well as each of the UCP2 
Trp mutants, were overexpressed in BL21 CD+. Overexpression of wt UCP2 and the 
three Trp mutants was achieved using the autoinduction method [52]. This was 
done by preparing 930mL of ZY media by dissolving 10g of Tryptone and 5g of yeast 
extract in a 2800mL Fernbach culture flask and then sterilizing by autoclaving on a 
liquid cycle with a 30min sterilization time.  The sterile media was then allowed to 
cool to room temperature overnight. The same day the ZY media was prepared an 
overnight culture was prepared under aseptic conditions, consisting of 20mL of L.B. 
broth in a 50mL falcon tube with 50µg/mL kan, 25µg/mL cam and 25µg/mL strep. 
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The overnight culture was then inoculated with the BL21 CD+ glycerol stock 
containing the desired UCP2-pET26b(+) construct and placed in a shaking incubator 
at 37°C with 240RPM shaking for 18h. Immediately prior to the end of the overnight 
incubation the ZY media was prepared for autoinduction via the addition of 1mL of 
1M MgSO4 followed by the addition of 50mL and 20mL of 20X NPS (0.5M (NH4)2SO4, 
1M KH2PO4, 1M Na2HPO4), and 50X5052 (25% glycerol (w/v) 2.5% glucose and 
10% lactose) respectively. Finally, kan, cam and strep were added, followed by the 
20mL overnight culture, yielding a final culture volume of 1L containing 1% 
Tryptone, 0.5% yeast extract, 1mM MgSO4, (NH4)2SO4, 50mM KH2PO4, 50mM 
Na2HPO4,  0.5%glycerol (w/v), 0.05% glucose, 0.2% lactose, 50µg/mL kan, 25µg/mL 
cam and 25µg/mL strep. The now fully prepared and inoculated autoinduction 
media was then placed in a shaking incubator and grown at 22°C with 250RPM of 
shaking for 22h.  The culture was split into centrifuge tubes and cells were collected 
by centrifuging at 8000xg for 15min at 4°C and then decanting the supernatant and 
transferring to a 50mL Falcon tube. The cell pellets were then stored at -20°C until 
used in the cell lysis experiment described below. 
3.2.4 Cell Lysis, Membrane Isolation, and Purification of Expressed UCP2 by IMAC 
 In order to extract and purify the desired UCP2 mutant proteins from the cell 
pellets they were thawed on ice and then resuspended in 50mL Extraction Buffer 
(E.B.) containing 20mM Tris-HCl, 0.5M NaCl, 0.5mg/mL DNase, 0.2mg/mL lysozyme 
and 1 c0mplete protease inhibitor cocktail tablet (Roche Applied Science), pH8.0. The 
resuspended cells were then incubated at 4°C for 20min to allow time for lysozyme 
digestion. Subsequently, the cells were loaded into the Constant Cell Distribution 
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System Model T2/40/BA/AA (Constant Systems) and passed through three times at 
20000p.s.i. The cell lysate was cleared of cellular debris and unbroken cells by 
centrifuging at 20000xg for 20min and then collecting the supernatant and 
discarding the pellet. The cell lysate was subjected to ultracentrifugation at 
50000RPM for 1h in a Optima™ Max ultracentrifuge (Beckman-Coulter) using an 
MLA80 rotor (Beckman-Coulter) to pellet the bacterial membranes. The supernatant 
was discarded and the pellets were fully resuspended in 30mL of Binding Buffer 
(B.B.) (20mM Tris-HCl, 0.5M NaCl, 1% N,N-dimethyldodecylamine-N-oxide also 
known as Lauryldimethylamine-oxide (LDAO), 20mM Imidazole and 1mM THP, 
pH8.0) by passing back and forth through a 20 gauge needle attached to a 5mL 
syringe and then transferring to a 25mL Erlenmeyer Flask with a stir bar at 4°C on a 
stir plate for 2h. At that point, any remaining insoluble particles were removed from 
the sample by a final centrifugation at 10000xg for 10min at 4°C.  Concurrently, an 
immobilized metal affinity chromatography (IMAC) gravity column containing 
~4mL of nickel-nitrilo-triacetic acid-Agarose beads (Ni-NTA-Agarose) (Qiagen) was 
prepared and equilibrated with 2 passes of 20mL of B.B. Following the final 
centrifugation the resuspended membrane, containing the overexpressed 
recombinant UCP2, was loaded onto the equilibrated IMAC column, the flow rate 
was set to ~1mL/min and the entire sample was passed through the column 3 times 
to allow for binding of the recombinant His-tagged UCP2 before the flow through 
was discarded [53]. The column was then washed with two passes of 20mL of Wash 
Buffer (20mM Tris-HCl, 0.5M NaCl, 1% Octyl-Glucoside (OG), 40mM imidazole and 
1mM THP, pH8.0), after which the bound protein was eluted using elution buffer 
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(20mM Tris-HCl, 0.5M NaCl, 1% Octyl-Glucoside (OG), 400mM imidazole 1mM THP, 
pH8.0) and ten 1mL fractions were collected . The concentration of protein in each 
collected fraction was then determined by Bradford assay using Bio-Rad Protein 
Assay Dye Reagent Concentrate (Bio-Rad) with a Bovine Serum Albumin (BSA) 
standard and the three most concentrated fractions were pooled [53]. The pooled 
fractions were afterwards exchanged into either desalt buffer (D.B.) (20mM Tris-
HCl, 50mM NaCl, 1% glycerol and 1% OG, pH8.0) or, if the isolated protein was to be 
reconstituted for the purposes of assaying its proton transport activity, 1.5X Proton 
Transport Internal Buffer (I.B.) (1x I.B.: 30mM [tris(hydroxymethyl)methyl]-2-
aminoethanesulfonic acid (TES) buffer, 80mM tetraethylammonium sulfate 
((TEA)2SO4),  and 1mM EDTA, pH7.2) using an Econo-Pac®10DG Desalting 
Prepacked Column according to the available general protocol [55] The isolated and 
purified recombinant UCP2 was then stored at -80⁰C until ready to be used, for 
protein stored in 1.5X I.B. this was a maximum of 18h. Purity of the protein samples 
obtained were assessed by SDS-PAGE stained with Coomassie blue. A second 
unstained SDS-PAGE gel was run and subsequently transferred to nitrocellulose 
using a semi-dry transfer, blocked overnight in 5%(w/v) skim milk powder in tris 
buffered saline with tween buffer (TBS-T) (10mM Tris-HCl, 150mM NaCl, 
0.05%(w/v) Tween 20, pH7.5) and the isolation of the target protein was verified by 
a Western blot that was developed using an anti-His primary antibody from a mouse 
host (Rockland Immunochemicals) and an anti-mouse/horseradish peroxidase 
conjugated secondary antibody from a rabbit host (Rockland Immunochemicals). A 
second Western blot was then performed, in order to definitively establish the 
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presence of UCP2 in the sample, using the same method just described but with the 
mouse anti-his primary antibody replaced by an anti-UCP1 primary antibody that 
was also from a rabbit host (Rockland Immunochemicals) and with the secondary 
antibody replaced by anti-rabbit/horseradish peroxidase conjugated secondary 
antibody from a goat host (Rockland Immunochemicals). 
3.2.5 Circular Dichroism Spectroscopy of Selective Trp Mutants of UCP2 
 After confirming that the desired UCP2 Trp mutants, as well as wt UCP2, 
were successfully produced, isolated and purified, the conformational equivalence 
of the mutants was confirmed by C.D. spectroscopy. To this end, purified stocks of 
wt UCP2 and each of the selective Trp mutants of UCP2 were retrieved from the -
80°C freezer and allowed to thaw on ice. Once fully thawed, a Bradford assay was 
performed, as described in previous sections, to determine the molar protein 
concentration in each stock. The stocks of protein used for C.D. spectroscopy 
experiments were then diluted to 8µM with D.B. Samples of each protein were then 
loaded into a clean quartz cell with a 0.1nm path length and far-UV C.D. 
measurements were obtained by scanning in Aviv 215 spectropolarimeter (Aviv 
Biomedical) at 25°C. All included spectra are the average of eight scans.  
3.2.6 Intrinsic Fluorescence Assays for Selective Trp Mutants of UCP2 
3.2.6.1 Sample Preparation or Intrinsic Fluorescence Measurements 
 After conformational equivalence of the selective Trp mutants of UCP2 was 
confirmed, with respect to the wt, the intrinsic fluorescence of each of the three 
selective Trp mutants of UCP2, as well as the wt, was next assessed. To do this, the 
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purified stocks of wt UCP2 and the UCP2 Trp mutants in D.B. were retrieved from 
the -80⁰C freezer and allowed to thaw on ice. Once the stocks were fully thawed a 
Bradford assay was performed using Bio-Rad Protein Assay Dye Reagent Concentrate 
(Bio-Rad) and BSA standards. Next, 4µM working stocks of each of the proteins were 
then made by diluting each with the required amount of D.B. and a Bradford was 
again performed as described above. The 4µM working stocks were then used to 
make as many 1mL 1µM samples as the following fluorescence assays required. 
3.2.6.2 Intrinsic Fluorescence Measurements 
To perform the desired intrinsic fluorescence measurements, 800µL of 1µM 
sample for each of the three UCP2 selective Trp mutants were obtained and total 
fluorescence and Trp fluorescence spectra from 200nm to 600nm were obtained by 
scanning with 280nm and 295nm excitation wavelengths, respectively. All scans 
were performed in a quartz cuvette with a 1cm pathlength (Hellma Analytics) using 
a Cary® Eclipse spectrofluorometer (Varian) with a scan rate of 600nm/min, the 
excitation slit width set to 5nm and detector voltage set to 800V. Between samples 
the cuvette was washed thoroughly with methanol, followed by ultrapure water and 
finally methanol again before it was dried under a 99.998% pure N2 gas stream. 
Blank samples containing only D.B. were also scanned under the same conditions. 
After the UCP2 samples were scanned another Bradford assay was performed, as 
described previously so that the fluorescence signals could later be standardized 
with respect to the micromolar concentration of protein in each sample. The spectra 
resulting from the blank scans were then subtracted from the protein sample scans 
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and the baseline-corrected spectrum for each of the UCP2 samples was 
subsequently standardized by dividing by its respective micromolar concentration. 
3.2.6.3 SDS Denaturation Assay 
 The effect of SDS denaturation on the Trp fluorescence spectrum of UCP2 
was next assayed, as was the effect of binding a known ligand, ATP, on said 
denaturation. To accomplish this, four sets of samples were prepared for each of the 
UCP2 Trp mutants and the wt UCP2, as described in section 3.2.5.2, as well as four 
blanks, containing only D.B. One set of UCP2 samples and one blank were scanned as 
described in the preceding section. Next, 20mM of SDS from a 693mM stock was 
added to each of the second set of samples and blank and these were again scanned 
using the conditions outlined in the preceding section. Following these scans, 50µM 
ATP was added to each of the third set of prepared samples, as well as the third 
blank, from a 100mM stock, before each was scanned again using the settings 
outlined in section 3.2.5.2 but with the detector voltage set to 750V. Finally, 20mM 
SDS and 50µM ATP were added to the fourth set of UCP2 samples and the fourth 
blank, from 693mM and 100mM stocks, respectively and were scanned using the 
same settings as were used for the previous samples. 
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3.2.7 Detergent Mediated Reconstitution and Acrylamide Quenching of UCP2 Trp 
Fluorescence 
3.2.7.1 Detergent Mediated Reconstitution of UCP2 for Quenching of Trp Fluorescence 
with Acrylamide 
 In order to study the UCP2 mutants in a more native-like environment, they 
were reconstituted into proteoliposomes, using detergent mediated reconstitution. 
First, 38µL of 100mg/mL of L-α-lecithin, in a chloroform methanol mix, was 
deposited into a 25mL round bottom flask, and dried under a stream of Ar gas. Any 
of the residual chloroform:methanol mixture was then evaporated by drying in a 
vacuum desiccator for 12h in the dark. After drying of the lipids was complete, the 
stock of the purified UCP2 mutant being reconstituted was obtained from the -80°C 
freezer and allowed to thaw completely on ice. The flask containing the dry lipids 
was then removed from the vacuum desiccator and the lipids were rehydrated with 
240µL of D.B. The flask was then gently vortexed to remove all of the lipid from the 
sides of the flask. Next, 10µL of C8E4 detergent was added from stock, to give a 
detergent:lipid ratio of 2.5, by mass and the flask was gently vortexed to mix. The 
lipids in the flask were then allowed to fully resolubilise before 100µL of the 
mixture was removed and mixed with 1.9mL of the selected purified UCP2 mutant 
in D.B. at stock concentration, which varied by experiment and was corrected for by 
performing protein assays on all samples and standardizing with respect to 
micromolar protein concentration. The resulting mixture was incubated at 4°C for 
30min with gentle stirring, yielding mixed micelles of detergent protein and lipid. 
Blank samples were also prepared in parallel with all protein samples by mixing 
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150µL of the lipid-detergent-buffer mixture with 2.85mL of D.B. and were also 
incubated at 4°C for 30min.  
Proteoliposome formation was then induced by removal of the detergents 
using SM-2 Biobeads (Bio-Rad). Each 1mL of sample and Blank was added to a 1mL 
spin column of SM-2 Biobeads (Bio-Rad) and incubated on a rotator at 4°C for 2h. 
After the two hour incubation, the samples were removed from the column by 1min 
of centrifugation at 1000RPM for in a Clinical 100 centrifuge (VWR). Every 1mL of 
sample or blank was then added to a second 1mL spin column of SM-2 Biobeads and 
incubated at 4°C on a rotator for 1h. The samples were again removed from the 
columns by centrifugation at 1000RPM for in a Clinical 100 centrifuge (VWR) for 
1min. The resulting samples and blanks were then used directly to run fluorescence 
quenching experiments with acrylamide, as described in the following section. 
3.2.7.2 Quenching of Trp Fluorescence with Acrylamide for UCP2 Reconstituted in 
Proteoliposomes 
 The reconstituted UCP2 samples and blank liposomes produced in section 
3.2.7.1 were used to run acrylamide quenching assays of UCP2 Trp Fluorescence 
with the aim of determining the accessibility of each of the two Trp residues present 
in UCP2. This was achieved by first loading 800µL of blank liposome into a quartz 
cuvette with a 1cm pathlength and scanning with 280nm and then 295nm 
excitation, using a Cary® Eclipse spectrofluorometer (Varian) with a scan rate of 
600nm/min and the excitation slit width set to 2.5nm and detector voltage set to 
800V. After the initial scan, 4µL of 9.447M acrylamide was added, the solution was 
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mixed in the cuvette by pipetting back and forth 3 times using a 10:100µL pipette 
(VWR) set to 50µL allowed to mix for 1min and then scanned again using the same 
conditions. Next, 19 more 4µL additions of 9.447M acrylamide were added with 
scans performed as described for the blank liposome, between each addition, 
thereby yielding 20 acrylamide data points for each sample, with the final 
concentration after each addition shown in table 5 and a final volume change of 
10%.  
The proteoliposome samples (800µL), containing the selected UCP2 Trp 
mutant or wt UCP2, were again scanned at 280nm and 295nm using the same 
conditions described for the blank. The same acrylamide additions and subsequent 
fluorescence scans were then made for the UCP2 samples, as described above, 
yielding 20 acrylamide data points for each sample, with the final concentration 
after each addition shown in table 5 and a final volume change of 10%. The resulting 
blank liposome spectra at each acrylamide point were subtracted from the 
corresponding UCP2 spectra at each acrylamide concentration, giving the baseline 
corrected spectra. A Bradford assay was then performed on each and the spectra for 
the UCP2 samples were then standardized by dividing by the micromolar 
concentration of protein, corrected for dilution after each acrylamide addition. The 
experiment was then repeated at pH 6.8 in the presence and absence of 100µM ATP. 
After all of the measurements were made and corrected for buffer effects and 
standardised with respect to micromolar concentration of protein in each sample, as 
well as the dilution after the given number of acrylamide additions, Stern-Volmer 
plots were generated by plotting the original fluorescence without acrylamide 
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divided by the fluorescence after a given number of acrylamide additions, against 
the molar concentration of acrylamide in the sample after those additions. The 
constants of dynamic quenching in each sample could then be derived from the 
slope of the linear trend line of each plot according to the relationship seen in 
equation 1. Where Kd is the constant of static quenching, [Q] is the concentration of 
quenching agent corresponding to a given peak fluorescence level F and F0 is the 
peak fluorescence in the same sample prior to addition of any quenching agent [41]. 
𝐹0
𝐹
= 𝑘𝐷[𝑄] + 1 (Equation 1) 
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Table 5: Acrylamide Concentration in Quenching Samples after a Given Number of 
Additions from a Stock: Concentration of acrylamide in fluorescence samples after a given 
number of 4µL additions from a 9.447M stock. 
#of Acrylamide Additions [Acrylanmide] (mM) 
0 0 
1 47 
2 93 
3 139 
4 185 
5 230 
6 275 
7 319 
8 363 
9 406 
10 449 
11 492 
12 534 
13 576 
14 617 
15 658 
16 699 
17 739 
18 778 
19 818 
20 858 
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3.2.8 UCP2 Proton Transport Assay 
3.2.8.1 Detergent Mediated Reconstitution of UCP2 for Proton Transport Assay 
 In order to study the UCP2 mutants in a more native-like environment, they 
were reconstituted into proteoliposomes, using detergent mediated reconstitution. 
First, 600µL of 100mg/mL of L-α-lecithin, in a chloroform methanol mix, was 
deposited into a 25mL round bottom flask, and dried under a stream of Ar gas. Any 
of the residual chloroform:methanol mixture was then evaporated by drying in a 
vacuum desiccator for 12h in the dark. After drying of the lipids was complete, the 
stock of the purified UCP2 mutant being reconstituted was obtained from the -80°C 
freezer and allowed to thaw completely on ice. The flask containing the dry lipids 
was then removed from the vacuum desiccator and the lipids were rehydrated with 
1.35mL of 10mM SPQ in ultrapure water. The flask was then gently vortexed to 
remove all of the lipid from the sides of the flask. Next, 150µL of C8E4 detergent was 
added from stock, to give a detergent:lipid ratio of 2.5, by mass and the flask was 
gently vortexed to mix. The lipids in the flask were then allowed to fully resolubilise 
before 3mL of the selected purified UCP2 mutant, in 1.5x I.B., was deposited and the 
resulting mixture was incubated at 4°C for 1h with gentle stirring, yielding mixed 
micelles of detergent protein and lipid. Proteoliposome formation was then induced 
by removal of the detergents using SM-2 Biobeads (Bio-Rad). Each 1mL of sample 
and Blank was added to a 2mL spin column of SM-2 Biobeads (Bio-Rad) and 
incubated on a rotator at 4°C for 2h. After the two hour incubation, the samples 
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were removed from the column by 1min of centrifugation at 1000RPM for in a 
Clinical 100 centrifuge (VWR). Every 1mL of sample or blank was then added to a 
second 2mL spin column of SM-2 Biobeads and incubated at 4°C on a rotator for 1h. 
The samples were again removed from the columns by centrifugation at 1000RPM 
for in a Clinical 100 centrifuge (VWR) for 1min. External SPQ was then removed by 
gel filtration on a 3mL spin column of coarse grade Sephadex-G25 (G.E. Healthcare) 
which was first equilibrated with I.B. Six such spin columns were produced for each 
proton transport experiment and 280µL of proteoliposome sample was added to 
each column before spinning at 2000RPM for 2min in a JS13.1 swinging bucket rotor 
(Beckman-Coulter). The gel filtered proteoliposomes were then collected and used 
to run proton transport experiments, as described in the following section. 
3.2.8.2 Proton Transport Assay for UCP2 
 To determine the proton flux rate, the kinetics of the change in SPQ 
fluorescence signal were measured with a Cary® Eclipse spectrofluorometer (Bio-
Rad) with all measurements made in a quartz cuvette with a 1cm pathlength.  SPQ 
fluorescence was excited at wavelength of 347nm and emission was monitored at 
442nm, with both the excitation and emission slit widths set to 5nm. During the 
scans the temperature was held constant at 25⁰C and the solution inside the cuvette 
was continuously stirred. Proton transport assay samples were prepared by mixing 
40µL of proteoliposomes from section 3.2.8.1 with 1.96mL of 1X external buffer 
(Ex.B.) (80mM K2SO4, 40mM K-TES, 1mM EDTA, pH7.2) in the cuvette and then 
scanning. At 30s into each scan 5µL of 40µM sodium palmitate (PA) was added to 
the cuvette and an increase in fluorescence signal was observed. At 1min 2µL of 
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1mM valinomycin (val) was added to begin proton transport. The kinetics of proton 
transport was then measured for the next 4min for a total time of 5min/scan. Blank 
measurements were also obtained by running liposomes prepared as described in 
section 3.2.8.1 but with the 1.5XI.B. that was added containing no protein. A 
minimum of 6 scans were performed for each protein sample every time the assay 
was performed (figure 11) [28]. 
 
Figure 11: Schematic Representation of the Proton Transport Assay: Diagram showing 
a basic representation of the proton transport assay used in this project. In brief: (1) the 
addition of valinomycin to proteoliposomes containing UCP@ with TES buffer and SPQ 
fluorescent probe contained in the internal compartment and a K+ gradient from the outside 
of the proteoliposomes to the inside, results in the influx of K+ into the proteolipsomes. 
Prior to this addition the charge is balanced on both sides of the model membrane and so 
the addition of valinomcyin results in a buildup of positive charge on the inside of the 
proteoliposomes. This excess positive charge in the internal compartment of the 
proteoliposomes then provides the driving force for FFA activated, UCP2-mediated 
transport of protons out of the proteoliposomes (2), thereby reducing the charge gradient. 
This efflux of protons results in the deprotonation of the TES buffer (3) to TES-, which 
subsequently quenches the fluorescence of SPQ (4)[28]. 
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 After the proton transport measurements were taken, the SPQ fluorescence 
signal was then calibrated by mixing 40µL of proteoliposome sample with 1.96mL of 
1XI.B. and mixed for 20 seconds before scanning using the same conditions used for 
measuring proton transport. At 20s in each scan 2µL of 1mM nigericin (K+/H+ 
ionophore) was added to the cuvette and a decrease in fluorescence was observed. 
At 45s and at every 15th second afterward until seven additions had been made, 2µL 
of 2M KOH was added to the cuvette. The calibration fluorescence was then fitted to 
the modified Stern-Volmer equation, equation 2. 
𝐹0
𝐹
= 𝑘𝑞[𝐻
+] + 1  (Equation 2) 
Where F0 is the fluorescence signal immediately prior to the first addition of KOH, F 
is the fluorescence signal after addition of KOH, kq is the Stern-Volmer constant and 
[H+] is the change of proton concentration in the media [28, 56]. The fitted 
calibration data was then used to determine kq which was subsequently utilized to 
convert fluorescence kinetic data into proton efflux using equation 3. 
 
[𝐻+] =
𝐹0−𝐹
𝐹
×
1
𝑘𝑞
  (Equation 3) 
 
 Next, the total internal volume of the proteoliposomes was determined for 
each set of scans. This was done by first mixing 40µL of proteoliposomes sample 
with 1.96mL of ultrapure water, mixing for 20s and then scanning using the same 
conditions outlined for measurement of proton transport. At 20s in each of the 
internal volume determination runs, 5µL of 0.25% (w/v) C8E4 was added to disrupt 
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the proteoliposomes and an increase in fluorescence was observed. At 45s and at 
every 15th second afterward, until seven additions had been made, 2.5µL of 100µM 
SPQ was added. The SPQ fluorescence signal was then plotted against the [SPQ]added 
to obtain the original concentration of SPQ in the proteoliposomes 
([SPQ]proteoliposomes). The [SPQ]proteoliposome was then compared to the original 
concentration of SPQ added to the sample ([SPQ]0=3mM) in order to determine the 
internal volume of the proteoliposomes via the relationship detailed in equation 4 
[28, 56]. 
𝑉(µ𝐿) =
[𝑆𝑃𝑄]𝑝𝑟𝑜𝑡𝑒𝑜𝑙𝑖𝑝𝑜𝑠𝑜𝑚𝑒
[𝑆𝑃𝑄]0
  (Equation 4) 
The initial rate of proton transport was then determined from the plot of proton 
efflux versus time to obtain the maximum transport rate vmax (mM/s). vmax was next 
converted to v’max (nmol/s) using equation 5. 
𝑣𝑚𝑎𝑥
′ (𝑛𝑚𝑜𝑙 𝑠⁄ ) =  𝑣𝑚𝑎𝑥(𝑚𝑀 𝑠⁄ ) × 𝑉(µ𝐿) (Equation 5) 
The rate of nonspecific proton leakage was determined by calculating the v’max of the 
protein-free blank liposome scans and was subsequently subtracted from the rate of 
proton transport for the proteoliposome samples. The transport rates were finally 
normalised with respect to protein concentration, which was determined as 
described in section 3.2.8.3. Final proton transport rates were reported in units of                      
µmol H+·min-1·mg protein-1 [28, 56]. 
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3.2.8.3 Determining Protein Concentration by TCA Precipitation and Modified Lowry 
Assay 
 To determine the protein concentration in the proton transport samples, 
50µL, 80µL and 100µL aliquots of each as well as BSA standards were diluted to 
1mL with ultrapure water were prepared in duplicate and then precipitated with 
100µL of 0.15% (w/v) sodium deoxycholate (DOC) and 100µL of pure HPLC grade 
trichloroacetic acid (TCA). The precipitates were pelleted in a microcentrifuge by 
spinning at 15000RPM and 4⁰C for 10min and the pellets were then redissolved in 
25µL of 20% (w/v) SDS. 100µL of reagent A’ from the Bio-Rad RC DC Protein Assay 
kit (Bio-Rad) was then added to each of the samples and standards, followed by bath 
sonication at room temperature for 5min and then 2min with no sonication before 
being bath sonicated again for 3min. 800µL of reagent B was then added to each of 
the samples and standards and they were incubated at room temperature for 30min 
before 300µL aliquots of each were added to a 96 well microplate and absorbance at 
750nm was measured in a microplate reader (Varian). 
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4 RESULTS 
4.1 Site-Directed Mutagenesis of UCP2 and Establishment of a 
Membrane-Targeted Recombinant Expression System in BL21 Codon 
Plus 
The first goal of the project was to remove the endogenous NcoI restriction site 
present in the cDNA of UCP2 by incorporating a silent mutation, so that an NcoI 
restriction site could be incorporated on the 5’ end to facilitate cloning into 
pET26b(+). This was accomplished using the site-directed mutagenesis technique 
known as primer-overlap extension PCR. In lane 4 of figure 12 a ~1kb band is seen, 
as was expected for a successful amplification and mutagenesis of UCP2 which 
meant that the project could proceed to the cloning of the His-tagged wt UCP2 into 
the pET26b(+) vector (henceforth referred to as wt UCP2-pET26b(+)). The 
pET26b(+) expression vector was chosen because it contains a pelB leader sequence 
which drives the targeting of attached proteins to the periplasm in gram negative 
bacteria. For an integral membrane protein such as UCP2, which by nature have a 
relatively high degree of hydrophobicity, the energy barrier for excretion through 
the membrane should be sufficiently high that the protein will not be able to pass 
through and will instead be embedded into the membrane [57]. 
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Figure 12: Agarose Gel Depicting the Results of NcoI Silencing in wt UCP2: An agarose 
gel showing the products of rounds one (lane 1), two (lane 2), and three (lane 4) of the site-
directed mutagenesis of UCP2 by primer overlap-extension PCR used to produce the His-
tagged UCP2 construct cloned into pET26b(+). 
 The newly produced His-tagged wt UCP2 NcoI knockout was gel purified and 
subsequently restriction digested with NcoI-HF and HindIII-HF in parallel with 
isolated empty pET26b(+). The digestion products were then gel purified and 
allowed to ligate overnight after which the product of the ligation reaction was used 
to transform DH5α E.coli cells and colonies were selected. The presence of the wt 
UCP2-pET26b(+) construct was confirmed by colony PCR (figure 13) and plasmid 
was isolated from colonies confirmed, by colony PCR,  to contain the wt UCP2-
pET26b(+) construct used to isolate plasmid, which was then sent to TCAG for DNA 
sequencing (see appendix 2 for complete sequencing results). Based on the DNA 
sequencing results a colony confirmed to contain the correctly produced and 
oriented His-tagged wt UCP2 in the pET26b(+) vector was selected and again grown 
up overnight and then used to make a glycerol stock. 
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Figure 13: Agarose Gel Depicting the Results of Colony PCR for Transformation of 
E.coli with wt UCP2-pET26b(+): 0.8% agarose gel with ethidium bromide incorporated 
and run at 120V for 1h before imaging on a VersaDoc 4000 Gel Imaging System (Bio-Rad) 
with a 100bp ladder. The gel shows the results of colony PCR on DH5α E.coli cells following 
their transformation with His-tagged wt UCP2-pET26b(+). The presence of bands at ~1kb is 
indicative of the presence of the His-tagged wt UCP2 insert in the selected colony. 
 
 The glycerol stock of the wt UCP2-pET26b(+) in DH5α was then used to 
inoculate an overnight culture which was then used to isolate wt UCP2-pET26b(+) 
plasmid. The isolated plasmid was then used as the template for the site-directed 
mutagenesis reactions used to produce the two single Trp mutants of UCP2 (W176Y 
and W283F). Tyr and Phe were chosen as substitutes for the W176 and W283 
residues, respectively, to minimise the impact of the mutations on the conformation 
of UCP2 based on the fact that they are the other two proteogenic aromatic amino 
acids and should be the most similar to Trp. The reason Tyr was chosen as the 
substitute for the W176 residue whereas Phe was chosen for the W283 residue, was 
because Tyr residues are more polar than Phe residues and predictions of the 
topology of UCP2 in membranes, based on hydropathy plots (figure 3A), place the 
W176 residue near the membrane interface and the W283 residue more towards 
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the middle of the membrane, in the hydrophobic tail region. The success of the PCR 
reactions was again confirmed by gel electrophoresis on a 0.8% agarose gel, as 
described above for His-tagged wt UCP2 with the endogenous NcoI restriction site 
knocked out. The single mutants were then, digested, cloned into pET26b(+) and 
transformed into DH5α E.coli cells as described previously for wt UCP2-pET26b(+). 
The success of the transformation reactions were then evaluated by colony PCR as 
described previously (figure 14) and the colonies confirmed to contain the plasmid 
and insert were used to grow overnight cultures before plasmid was isolated and 
sent to TCAG for sequencing (see appendix 2 for full sequencing results). A colony 
that was confirmed by sequencing to contain the full length UCP2 coding sequence 
with the desired mutation incorporated (TGGTAC and TGGTTC for W176Y and 
W283F, respectively) was selected for each mutant, then grown overnight and used 
to prepare a glycerol stock. 
 
Figure 14: Agarose Gel Depicting the Results of Colony PCR for Transformation of 
E.coli with W176Y and W283F UCP2-pET26b(+): 0.8% agarose gel with ethidium 
bromide incorporated and run at 120V for 1h before imaging on a VersaDoc 4000 Gel 
Imaging System (Bio-Rad) with a 1 kb ladder. The gel shows the results of colony PCR on 
DH5α E.coli cells following their transformation with His-tagged W176Y UCP2-pET26b(+) 
(lanes 1-5) and His-tagged W283F UCP2-pET26b(+) (lane 7-10). The presence of bands at 
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~1kb is indicative of the presence of the His-tagged UCP2 Trp mutant insert in the selected 
colony. 
 
 The glycerol stock of the W176Y UCP2-pET26b(+) in DH5α was then used to 
inoculate an overnight culture which was then used to isolate W176Y UCP2-
pET26b(+) plasmid. The isolated plasmid was then used as the template for the site-
directed mutagenesis reactions used to produce the double Trp mutant of UCP2 
(W176Y-W283F). The success of the PCR reactions was again confirmed by gel 
electrophoresis on a 0.8% agarose gel, as described above for His-tagged wt UCP2 
with the endogenous NcoI restriction site knocked out (figure 15). The W176Y-
W283F mutant was then, digested, cloned into pET26b(+) and transformed into 
DH5α E.coli cells as described previously for wt UCP2-pET26b(+). The success of the 
transformation reactions were then evaluated by colony PCR as described 
previously and the colonies confirmed to contain the plasmid and insert were used 
to grow overnight cultures before plasmid was isolated and sent to TCAG for 
sequencing (figure 16, see appendix 2 for full sequencing results). A colony that was 
confirmed by sequencing to contain the full length UCP2 coding sequence with the 
desired mutation incorporated (TGGTAC and TGGTTC for W176Y and W283F, 
respectively) was selected for each mutant, then grown overnight and used to 
prepare a glycerol stock. 
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Figure 15: Agarose Gel Depicting the Results of Site-Directed Mutagenesis of W176Y 
UCP2 to W176Y-W283F: 0.8% agarose gel with ethidium bromide incorporated and run at 
120V for 1h before imaging on a VersaDoc 4000 Gel Imaging System (Bio-Rad). The gel 
shows the products of rounds one (lane 1), two (lane 2), and three (lane 4) of the site-
directed mutagenesis of UCP2 by primer overlap-extension PCR used to produce the His-
tagged W176Y-W283F UCP2 mutant. 
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Figure 16: Result for T7 Terminator Primed DNA Sequencing of W176Y-W283F UCP2-
pET26b(+): The results of DNA sequencing of the W176Y-W283F UCP2-pET26b(+) plasmid 
with a T7 terminator primer (Query line) aligned with the wt UCP2 mRNA sequence using 
the nucleotide Basic Local Alignment Search Tool (nBLAST) available from NCBI [58]. The 
top and bottom blue boxes show the nucleotide changes resulting in the W283F and W176Y 
mutations, respectively. The red box shows the silent mutation introduced to knockout the 
endogenous NcoI restriction site. 
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 Once it was confirmed by DNA sequencing that all of the required UCP2-
pET26b(+) constructs had been produced and successfully transformed into DH5α, a 
plasmid isolation was performed for each of them and the isolated plasmid was then 
used to transform BL21 CD+. Plasmid was again isolated for each of the UCP2 
constructs, this time from BL21 CD+ and sent to TCAG for DNA sequencing and it 
was confirmed that each of the UCP2-pET26b(+) constructs was successfully 
transformed into BL21 free of any undesired mutations (figure 16, see appendix 2 
for full sequencing results). 
4.2 Membrane-Targeted Expression of hUCP2 Mutants in BL21 Codon 
Plus and Purification by IMAC 
 After it was confirmed by DNA sequencing that all of the UCP2-pET26b(+) 
constructs that were required for the project had been produced and successfully 
cloned into BL21 CD+ the next step was to overexpress each of the UCP2 mutants, 
and the wt by autoinduction using the method that had been established for UCP1 
by prior work done in our lab and outlined in detail above in section 3.2.7 [57]. The 
cells were then lysed as previously described and the success of the expression of wt 
UCP2 and the selective Trp mutants as well as its targeting to the bacterial 
membrane were confirmed by: isolating the bacterial membranes via differential 
centrifugation; purifying the UCP from the bacterial membrane via IMAC; and finally 
detecting the presence of UCP2 in the purified samples by western blot (see figures 
17 and 18). 
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 Figure 17 shows single bands in each lane of a western blot with an anti-6X 
his antibody, corresponding to the typical apparent Mw of UCP2 monomer bands on 
an SDS-PAGE gel, which is ~25kDa [40]. The lanes in the western blot were loaded 
with wt UCP2, W176Y, W283F and W176Y-W283F therefore confirming the 
confirming their expression into the bacterial membrane and successful isolation by 
differential centrifugation and IMAC. In order to definitively confirm UCP2 as the 
source of the bands seen in the anti-his western blot a second western blot was run 
with an anti-UCP1 antibody with established cross-reactivity with UCP2 [59]. Figure 
18 shows the results of the anti-UCP1 western blot with bands again apparent at 
~25kDa which is the expected Mw for the UCP2 monomer. Interestingly bands at 
~50kDa and ~100 kDa were detected in the anti-UCP1 western blot, potentially 
corresponding to dimer and tetrameric bands, as previously reported for UCP1 [57]. 
The SDS-PAGE gel shown in figure 19 was run with purified stocks of wt UCP2 and 
each of the selective Trp mutants.  The presence of multiple bands in each lane of 
the SDS-PAGE gel, especially the bands corresponding to Mw values higher than that 
of UCP2 (apparent Mw ~30kDa), is problematic and may explain the fluorescence 
results obtained, as discussed below in chapter 5. Nevertheless, due to the presence 
of higher molecular weight bands in the anti-UCP1 western blot and previous work 
showing the effectiveness of the same purification system for UCP1, these bands 
were potentially misattributed to oligomerization of UCP2 and the project moved 
forward to fluorescence assays [57]. 
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Figure 17: Western Blot of Purified Stocks of wt UCP2 and Selective Trp Mutants – 
Anti-His: Chemiluminescent western blot detection of his-tagged wt UCP2 and the selective 
Trp mutants of UCP2 using anti-his primary antibody from a mouse host and an anti-
mouse/HRP conjugated secondary antibody from a rabbit host. The bands present between 
37kDa and 25kDa are indicative of the presence of his-tagged recombinant UCP2. Lanes 1-4 
were loaded with purified samples of wt UCP2, W176Y UCP2, W283F UCP2 and W176Y-
W283F UCP2, respectively. 
 
 
Figure 18: Western Blot of Purified Stocks of wt UCP2 and Selective Trp Mutants – 
Anti-UCP1: Chemiluminescent western blot detection of his-tagged wt UCP2 and the 
selective Trp mutants of UCP2 using anti-UCP1 primary antibody from a rabbit host and an 
anti-rabbit/HRP conjugated secondary antibody from a goat host. The bands present 
between 37kDa and 25kDa are indicative of the presence of his-tagged recombinant UCP2. 
Lanes 1-4 were loaded with purified samples of wt UCP2, W176Y UCP2, W283F UCP2 and 
W176Y-W283F UCP2, respectively. 
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Figure 19: SDS-PAGE Gel Run with Purified Stocks of wt UCP2 and Selective Trp 
Mutants: SDS-PAGE gel, stained with Coomassie Blue, showing the results of the 
purification of UCP2 wt and Trp mutants from BL21 by differential centrifugation, IMAC and 
desalting. Lanes 1-4 were loaded with the purified stock of wt UCP2, W176Y, W283F and 
W176Y-W283F, respectively. 
 
4.3 Confirmation of the Conformation Equivalence of the Selective Trp 
Mutant of UCP2 by Far-UV CD Spectroscopy 
 Once the successful production, membrane targeting and purification of the 
selective Trp mutants of UCP2, as well as wt UCP2, had been confirmed by SDS-PAGE 
and western blot the next goal was to confirm that the selective Trp mutants retained 
conformational equivalence to wt UCP2. This was done by far-UV CD spectroscopy scans 
overlaying them as described in section 3.2.5 (figure 20). As can be seen in figure 20, the 
Trp mutants retained dominantly helical conformations as evidence by the local minima 
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at 208nm and 222nm. It can also be seen that the selective Trp mutants retain 
conformational equivalence with the wt protein as evidenced by the overlapping of the 
W176Y-W283F mutant’s far-UV CD spectrum with that of the wt. Despite a slight gap 
between the spectra, the W176Y and W283F mutants were also confirmed to retain 
conformational equivalence with the wt protein based on the overall secondary 
structure composition of the proteins, with the difference seen in the absolute molar 
elipticity accounted for by the error range in the protein assay used to determine the 
[UCP2] in each sample. 
 
Figure 20: Far-UV CD Spectra of Selective Trp mutants of UCP2: Far-UV CD spectra of 
selective Trp mutants of UCP2 and wt UCP2 in a detergent system consisting of 1% OG. 
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4.4 Intrinsic Fluorescence Based Assays for Selective Trp Mutants of 
UCP2 
4.4.1 Intrinsic Fluorescence Measurement in Detergent 
 The fluorescence of the purified selective Trp mutants of UCP2 was assessed 
and compared against the wt fluorescence. For each sample both the total intrinsic 
fluorescence (excitation at 280nm) and the tryptophan specific fluorescence 
(excitation at 295nm) was measured (figure 21). The intrinsic fluorescence based 
assays did not show the expected low intrinsic fluorescence for the double mutant 
when excited at 295nm. Furthermore, it was expected that there would be a 
stepwise decrease in the fluorescence of the proteins samples with wt UCP2 having 
the highest fluorescence, followed by each of the single Trp mutants (W176Y and 
W283F) and finally the W176Y-W283F double Trp mutant having the lowest. 
However, this was not the case, as can be seen in Trp fluorescence spectra shown in 
figure 21B, which shows the peak of the wt UCP2 roughly overlapping with the 
W283F mutant and the peak of the W176Y mutant roughly overlapping with that of 
the W176Y-W283F double mutant. The overlap between the wt UCP2 and W283F 
and between W176Y and W176Y-W283F suggests that the fluorescence of the 
W283 residue may be fully quenched in the wt protein. 
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Figure 21: Intrinsic Fluorescence Spectra of Selective Trp mutants of UCP2: 
Fluorescence of purified samples of selective Trp mutants of UCP2 as well as the wt, in D.B. 
with excitation at 280nm (A) and 295nm (B) standardized with respect to micromolar 
concentration of protein in each sample. 
 
 Due to the unexpectedly high baseline fluorescence observed for the W176Y-
W283F UCP2 mutant in the Trp emission spectrum more scans were run under 
varying buffer and scan conditions in order to determine the source of the 
aberration with the aim of mitigating it. The additional scans however, all showed 
the same high Trp fluorescence signal for the W176Y-W283F UCP2 mutant. Aside 
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from the high background fluorescence for the double knockout mutant the Trp 
fluorescence spectra shown in figure 21B still demonstrated a clear difference 
between the Trp fluorescence of the W176Y and W283F mutants, with higher peak 
fluorescence for the W283F mutant that was slightly red-shifted relative to the 
W176Y mutant. 
4.4.2 SDS Denaturation Assay 
 In order to potentially help distinguish between the Trp fluorescence of the 
W176Y single mutant and the W176Y-W283F double mutant and also to investigate 
the position of the nucleotide binding site within the folded structure of UCP2 an 
SDS denaturation assay was devised in which the UCPs being examined were 
scanned to obtain baseline fluorescence measurements and then denatured by the 
addition of 20mM SDS in the presence and absence of 50µM ATP. It was expected 
that if the previously observed overlap between the fluorescence peaks of the wt 
UCP2 and W283F and between W176Y and W176Y-W283F were due to the 
quenching of W283 by some amino acid in close proximity or some other effect of 
protein folding, then upon SDS denaturation the expected stepwise decrease in the 
Trp fluorescence of the proteins, detailed in the previous section, would be 
observed. It was also expected that due to the predicted presence of the nucleotide 
binding site of UCP2 in close proximity to the W283 Trp residue there would be a 
lower increase in the peak Trp fluorescence of W176Y with 50µM ATP upon 
denaturation with 20mM SDS relative to W176Y with no ATP added due to the 
expected increase in stability of the local environment around W283 that would 
accompany ATP binding. By extension, the aforementioned effect of ATP addition 
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prior to denaturation with SDS for the W176Y should also be present for wt UCP2, 
should be decreased or absent for the W283F mutant and should be entirely absent 
for the W176Y-W283F double mutant. 
 
Figure 22: Fluorescence Spectra from SDS Denaturation Assay (All Conditions): 
Results of SDS denaturation assay showing scans of purified samples of selective Trp 
mutants of UCP2 as well as the wt, in D.B. with nothing added (A), 20mM SDS added (B), 
50µM ATP (C) and both 50µM ATP and 20mM SDS (D). Excitation was at 295nm, and the 
spectra were standardized with respect to micromolar concentration of protein in each 
sample. 
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Figure 23: Fluorescence Spectra from SDS Denaturation Assay (All Mutants): Results 
of SDS denaturation assay showing scans of purified samples of wt (A), W176Y (B), W283F 
(C) and W176Y-W283F (D) UCP2, in D.B. with 50µM ATP added, 20mM SDS added, and both 
50µM ATP and 20mM SDS added. Excitation was at 295nm, and the spectra were 
standardized with respect to micromolar concentration of protein in the samples. 
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 Figures 22 and 23 show the results of the SDS denaturation assay of the 
selective Trp Mutants of UCP2 and wt UCP2. Figure 22A shows the results of the 
denaturation of wt UCP2 and the selective Trp mutants and demonstrates that 
denaturation did not restore the expected stepwise decrease in fluorescence 
between UCP2 wt, the single Trp mutants (W176Y and W283F) and the W176Y-
W283F double mutant. Figure 23A displays the results of the SDS denaturation 
assay for the W176Y mutant and shows that W283 has maximum fluorescence in 
the folded UCP2 as evidenced by the lack of a significant increase in fluorescence 
signal upon denaturation with SDS, indicating it may be fully exposed to solvent in 
the folded UCP2. Figure 23A shows a clear decrease upon binding of ATP, which is 
not fully mitigated by denaturation with SDS. There is also a slight blue-shift in the 
peak emission wavelength of the W176Y mutant upon the addition of ATP. The 
results for the SDS denaturation assay performed on the W283F are displayed in 
figure 23B and shows that the fluorescence of the W176 residue was not increased 
by the addition of SDS alone suggesting either full exposure of the W176 residue to 
begin with or a highly stable local environment around W176. Figure 23B also 
shows a decrease in W176 fluorescence upon the addition of 50µM ATP, although 
the decrease is markedly smaller than the one observed for W283. This suggests 
that W176 is also close to the site of ATP binding in UCP2 but that W283 is closer or 
alternatively, that changes in the conformation of UCP2 upon binding of ATP, result 
in partial quenching of W176. Interestingly, the W283F fluorescence spectrum also 
shows that the addition of both ATP and SDS results in an increase in the 
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fluorescence signal of W176, implying that binding of ATP by UCP2 may lead to 
decreased stability around the W176 residue. Finally, while still retaining an 
unexpectedly high fluorescence signal overall, the spectra for the W176Y-W283F, 
seen in figure 23C double Trp mutant, containing no Trp residues was not sensitive 
to the addition of 20mM SDS, 50µM ATP or both 50µM ATP and 20mM SDS, which 
was the expected result. 
4.5 Acrylamide Quenching of Selective Trp Mutant of UCP2 
 Reconstituted into Liposomes 
 The next step in this project was to the run fluorescence quenching assays 
with acrylamide on the selective Trp mutants of UCP2, as well as the wt protein, 
after reconstitution into model liposomes of L-α-Lecithin using a slight modification 
of the previously established detergent mediated reconstitution method for the 
UCPs [28]. The aim of this portion of the study was to distinguish between the 
accessibility of the two Trp residues present in UCP2 to the acrylamide quencher, 
while embedded in a model membrane and thereby provide insight into the overall 
membrane topology of UCP2. Additionally, acrylamide quenching experiments were 
performed at pH 6.8 in the presence and absence of 100µM ATP in order to provide 
further insight into the position of the nucleotide site in UCP2. The results of the 
acrylamide quenching experiments are shown in figures 24-27 and table 6. 
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Figure 24: Acrylamide Quenching Spectra of wt UCP2 : Spectra obtained from 
fluorescence quenching with acrylamide for wt UCP2 at pH 8.0 and excitation at 295nm. 
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Figure 25: Acrylamide Quenching Spectra of W176Y-W283F UCP2: Spectra obtained 
from fluorescence quenching with acrylamide for W176Y-W283F UCP2 at pH 8.0 and 
excitation at 295nm. 
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Figure 26: Acrylamide Quenching Data: Stern-Volmer Plot for Quenching of wt UCP2 
and W176Y-W283F UCP2 at pH8: Stern-Volmer plot for the results of acrylamide 
quenching of wt UCP2 and W176Y-W283F UCP2 at pH 8.0 and excitation at 295nm. 
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Figure 27: Acrylamide Quenching Data: Stern-Volmer plot for the results of acrylamide 
quenching of wt (A), W176Y (B), W283F (C) and W176Y-W283F (D) UCP2 at pH 6.8, with 
and without 100µM ATP and excitation at 295nm. 
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Table 6: Quenching Constants obtained from Fluorescence Quenching of Selective Trp 
Mutants of UCP2: Summary of the dynamic quenching constants found for acrylamide 
quenching of wt and selective Trp mutants of UCP2 with their corresponding standard 
errors. 
UCP2 Mutant 
Kd at 
pH8 
(M-1) 
Std. 
Error 
(+/-) 
(M-1) 
Kd at 
pH6.8     
No ATP 
(M-1) 
Std. 
Error 
(+/-) 
(M-1) 
Kd at      
pH6.8     
+ ATP 
(M-1) 
Std. 
Error 
(+/-) 
(M-1) 
Wt 1.5919 0.1169 1.2556 0.0708 1.3023 0.0563 
W176Y 1.7452 0.1637 1.0937 0.1321 1.1996 0.1166 
W283F 2.1408 0.2894 1.3430 0.0832 1.1416 0.0882 
W176Y-
W283F 
1.3266 0.1629 1.1890 0.0670 1.1713 0.09896 
 
 The fluorescence quenching assays for the UCP2 Trp mutants at pH 8 showed 
that there was a small increase in the accessibility of the single Trp mutants (W176Y 
and W283F) to the acrylamide quencher relative to the double mutant but no 
discernible difference for the single Trp mutants relative to each other (figure 26 
and table 6). The results also showed that quenching occurred for wt UCP2 and all of 
the UCP2 mutants, including the double mutant, which was expected to be 
completely insensitive to acrylamide quenching (figures 26 and 27D, table 6). 
Figures 27 and table 6 show the results of the acrylamide quenching experiments at 
pH6.8, with and without the addition of 100µM ATP. At 100µM ATP UCP2 should be 
totally inhibited, however the findings show that no significant changes occur in the 
accessibility of the acrylamide quencher to the Trp residues found in the UCP2 
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samples upon ATP binding [28]. Furthermore, the results also show that at pH6.8 
there is a slight difference in the accessibility of the Trp residues found in the 
W176Y and W283F samples, with Kd values 1.0937M-1 +/- 0.1321M-1 and 1.3430M-1 
+/- 0.0832M-1, respectively. The results also show a slight difference in the 
accessibility of Trp residues in the ATP bound wt UCP2 and ATP bound W283F 
UCP2 samples, with Kd values of 1.3023M-1 +/- 0.0563M-1 and 1.1416M-1 +/- 
0.0882M-1, respectively. The Kd values shown in table 5 also demonstrate a 
significant decrease in the accessibility of the Trp residues to acrylamide when the 
pH was lowered from 8 to 6.8. 
4.6 Proton Transport Assays for Selective Trp Mutants of UCP2 
 The final goal of this project was to examine the role of the two Trp residues 
present in UCP2 in the proton transport activity of the protein. To accomplish this, 
the proton transport assay that was previously described in [28] was applied to 
reconstituted samples of wt UCP2 and double mutant UCP2. The results of these 
assays are shown in figures 28-31 and table 7 shows the computed average specific 
proton transport rates for each protein. As can been seen in figures 30 and 31 below 
the W176Y-W283F UCP2 mutant retained proton transport activity but, as shown in 
table 7, had a decreased specific transport rate relative to the wt protein (2.973101 
+/- 0.335897 µmol·min-1·mg of protein-1  versus 4.052575 +/- 0.435703µmol·min-
1·mg of protein-1, respectively). 
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Figure 28: Proton Flux Rate over Time for the First Round of Proton Transport Assay 
Applied to wt UCP2: Average of 5 scans showing proton efflux over time for round 1 of the 
proton transport assay performed on wt UCP2 reconstituted in L-α-Lecithin. 
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Figure 29: Proton Flux Rate over Time for the Second Round of Proton Transport 
Assay Applied to W176Y-W283F UCP2: Average of 5 scans showing proton efflux over 
time for round 2 of the proton transport assay performed on wt UCP2 reconstituted in L-α-
Lecithin. 
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Figure 30: Proton Flux Rate over Time for the First Round of Proton Transport Assay 
Applied to W176Y-W283F UCP2: Average of 5 scans showing proton efflux over time for 
round 1 of the proton transport assay performed on W176Y-W283F UCP2 reconstituted in 
L-α-Lecithin. 
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Figure 31: Proton Flux Rate over Time for the Second Round of Proton Transport 
Assay Applied to W176Y-W283F UCP2: Average of 5 scans showing proton efflux over 
time for round 2 of the proton transport assay performed on W176Y-W283F UCP2 
reconstituted in L-α-Lecithin. 
 
Table 7: Specific Proton Transport Rates for wt and W176-W283F UCP2: Calculated 
average specific proton transport rates based on the results of two rounds of the proton 
assay for both wt UCP2 and W176Y-W283F. Reported specific transport rates are the 
average of 11 scans. 
 Wt UCP2 W176Y-W283F UCP2 
Average Specific Flux Rate 
(µmol·min-1·mg of protein-1) 
4.052575 2.973101 
Standard error 0.435703 0.335897 
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5 DISCUSSION 
The original objectives of this study, including producing selective Trp mutants of 
UCP2 cDNA by overlap extension PCR, introducing these mutants into a membrane 
targeting expression vector, expressing, isolating and purifying UCP2 protein for 
each of the mutants and the wt, confirming that the selective Trp mutants retained 
conformational equivalence to the wt and then running fluorescence spectroscopy 
based assays on the purified proteins, were successfully completed. However, no 
clear difference could be observed in the membrane topology of the W176 residue 
versus the W283 residue, as evidenced by the lack of discernable difference in the 
accessibility of the two residues to the acrylamide quencher. Another unexpected 
result was the presence of a fluorescence signal in all double mutant fluorescence 
scans with excitation at 295nm, which was of a similar magnitude to the 
fluorescence signal obtained for the Trp containing UCP2 samples. Finally, it was 
observed that the Trp residues did indeed have an effect on the proton transport 
activity of UCP2 as evidenced by the marked decrease in the specific transport rate 
of the W176Y-W283F mutant relative to wt UCP2. 
5.1 Interpretation of Fluorescence Results 
 The results of the fluorescence assays performed on UCP2 in detergent 
appear to show that the W283 residue in UPC2 is normally quenched within the 
folded protein, as evidenced by the fact that when excited at 295nm the 
fluorescence spectrum for the W176Y mutant roughly overlaps with that of the 
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W176Y-W283F double mutant. This conclusion is also supported by the fact that the 
fluorescence of the W283F mutant roughly overlaps with that of wt UCP2 as the 
differences between the fluorescence peak of each single Trp mutant with the 
W176Y-W283F double mutant should be additive to the fluorescence of the wt 
protein. The results of the SDS denaturation assay (figures 22-23) however, do not 
support this conclusion as, if this were the case, it would be expected that upon the 
addition of a denaturant such as SDS the fluorescence signal of the W176Y mutant, 
when excited at 295nm, would have increased as would that of the wt UCP2, neither 
of which were observed.  
 The results of the SDS denaturation assay for W176Y (figure 23B) initially 
appear to show that ATP does indeed bind in the vicinity of the W283 residue, as 
expected. This is based on the significantly lower fluorescence signal observed for 
excitation of W176Y at 295nm upon the addition of 50µM ATP, relative to the 
W176Y with no ATP added and further supported by the fact that this was no totally 
mitigated by denaturation with SDS. However, the results of the acrylamide 
quenching studies (figure 27B and table 6) failed to show any difference in 
accessibility of the W283 residue to acrylamide quencher in the presence versus 
absence of 100µM ATP. Taken together these results seem to suggest that the 
binding of ATP by UCP2 results in a shift in the conformation, as previously shown 
by CD spectroscopy, leading to increased stability of the local environment around 
W283 but this should not result in both the blue shift in the peak emission and 
decrease in fluorescence seen in figure 23B [28]. A similar trend was also obtained 
for the SDS denaturation assay when it was performed on W283F (figure 23C) but 
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with the overall decrease in fluorescence upon binding of ATP lessened and an 
increase in fluorescence observed upon addition of both ATP and SDS, suggesting 
that binding of ATP destabilizes the environment around W176. The results of the 
acrylamide quenching assays performed on UCP2 reconstituted into liposomes of L-
α-lecithin could not distinguish between the accessibility of the two TRP residues 
present in UCP2, to the acrylamide quencher and showed no change in the 
accessibility when 100µM ATP was added, under which conditions UCP2 should be 
fully inhibited. This contrasts with the work of Viguera et al. (1992) which found a 
significant difference in acrylamide quenching of the two equivalent Trp residues 
found in UCP1 [60] Unfortunately, the high fluorescence signal, when excited at 
295nm, seen for the W176Y-W283F double mutant in all of the fluorescence assays 
performed, make it impossible to draw any definitive conclusion about the structure 
or folding of UCP2 in membranes because the fluorescence spectra obtained, as well 
as any changes within them under differing conditions cannot be related solely to 
the contributions of the Trp residues found in UCP2. 
5.2 Reasons for Tryptophan Fluorescence Signal in Purified W176Y-
W283F UCP2 
 In general, there are only two possible reasons why there could be a 
fluorescence signal for W176Y-W283F UCP2, when excited at 295nm, given that the 
DNA sequencing results show correct incorporation of the desired mutations into 
the UCP2 gene., Either there is significant contamination of the purified UCP2 
proteins with another Trp containing protein and thus another source of 
tryptophan; or there is another fluorophore present in the purified samples with a 
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similar excitation and emission range to tryptophan. The former, and  seemingly 
more likely, scenario is supported by the observation that the dynamic quenching 
constants obtained for acrylamide quenching of W176Y-W283F are similar to those 
obtained for the wt and single Trp mutants of UCP2, as acrylamide should be a 
specific quencher of Trp fluorescence only [41,61]. However, the presence of bands 
corresponding to the expected apparent Mw of ~30kDa for UCP2 on anti-his and 
anti-UCP1 (figures 17 and 18) western blots would seem to suggest that this is not 
the case. However, the SDS-PAGE gel in figure 19 shows the majority of the protein 
in the sample is concentrated in a band at 25kDa, which is lower than the expected 
Mw for UCP2 and therefore may be represent an artifact of the protein expression 
system, such as a partially expressed truncated UCP2 or significant contamination If 
this were the case, based on the aforementioned, SDS-PAGE results, the contribution 
to the spectra of the purified UCP2 samples by non-UCP2 contaminants would be 
significant and fluorescence scans of the W176Y-W28F mutant excited at 295nm 
would retain the majority of the fluorescence signal of wt UCP2, as was seen. 
Therefore, three plausible scenarios remain in which contamination could explain 
the data obtained. The first is that the band at ~150kDa seen in the SDS-PAGE gel 
consists of a protein that was co-isolated with UCP2 and which contains significantly 
more than two Trp residues, all of which are fully solvent exposed, thereby still 
explaining the lack of signal change in W176Y-W283F after denaturation with SDS. 
The second is based on the fact that highly hydrophobic membrane proteins may 
still aggregate under the detergent conditions used for the purification of UCP2 and 
if the aggregation was strong enough, would not be soluble in SDS and therefore not 
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seen on an SDS-PAGE gel [62, 63]. The third and final scenario in which 
contamination with a protein other than UCP2 could explain the resultsis the 
possibility that UCP2 associates with another protein in the bacterial membrane and 
in 1% LDAO and 1% OG resulting in the co-purification of the unknown second 
protein which also has an apparent Mw of ~25kDa on an SDS-PAGE gels. The 
aforementioned association is then disrupted by the harsher denaturing conditions 
of SDS-PAGE leading to the purified UCP2 stocks to appear pure but the majority of 
the protein present is actually UCP2. This scenario may also explain the apparent 
faintness of the bands seen on the Western blots at ~25kDa relative to the thick 
dark band seen on the SDS-PAGE gel. To test this possibility a blue native PAGE gel 
should be run, as this method does not use harsh denaturing conditions like those 
typically used for SDS-PAGE gels. If this were indeed the case it would be expected 
that on the blue native PAGE gel the large band at just above the 25kDa mark. 
Alternatively, to determine if contamination with a non-UCP2 protein is responsible 
for the band seen at ~25kDa, the band could be excised and subjected to mass 
spectrometry.  
 Another seemingly less likely scenario, in which the fluorescence signal seen 
in W176Y-W283F when excited at 295nm is due to a fluorophore other than 
tryptophan, but with very tryptophan-like spectral properties, being present in the 
purified UCP2 samples must be due to some fluorophore present in the samples 
themselves as it is not observed in blank scans of just the buffer. Given this fact, the 
only plausible, however still unlikely explanation is that one or more of the 11 
tyrosine residues present in wt UCP2 is deprotonated in the ground state under the 
  88 
scan conditions giving tyrosinate[64-67]. Tyrosinate has a similar emission 
wavelength to tryptophan, at ~345nm and its fluorescence is virtually 
indistinguishable from tryptophan and despite the normal pKa value of 10.01 for the 
phenol group of tyrosine it has previously been reported in proteins at neutral pH 
[41, 64]. However, in order for this to occur there usually must be an excited state 
deprotonation of the tyrosine residue by a nearby carboxylic group on an aspartate 
or glutamate residue. Therefore, since the tyrosine residues should not be 
appreciably excited at 295nm, especially in the later assays where the excitation slit 
width was reduced to 2.5nm in order to better control for the possibility of tyrosine 
emission this is not likely to be the case for UCP2 [64]. Moreover, the fact that the 
W176Y-W283F mutant was still quenched by acrylamide strongly suggests that 
tyrosinate fluorescence is not responsible for the unexpected fluorescence results 
obtained for the double Trp mutant of UCP2. 
5.3 The Role of Trp Residues in Proton Transport by UCPs 
 Tryptophan residues are the largest, most energetically expensive to produce 
and consequently, the rarest of the 20 standard proteogenic amino acids. Therefore, 
the presence of two Trp residues that are conserved in all five human uncoupling 
proteins strongly suggests that they play a critical role in either maintaining the 
correct folding or in the ion transport activity of the protein. The results of the 
proton transport assays shown in figures 28-31 and table 7, which show a ~25% 
decrease in the specific transport rates of W176Y-W283F UCP2 (2.973101 +/- 
0.335897 µmol·min-1·mg of protein-1 versus 4.052575 +/- 0.435703µmol·min-1·mg 
of protein-1, respectively) taken together with the established conformational 
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equivalence of the selective-Trp mutants of UCP2 based on far-UV CD spectroscopy, 
indicates that the role of the conserved Trp is primarily in the ion transport activity 
of the UCPs and not in maintaining correct folding of the protein in the membrane. 
Due to time constraints the proton transport assay was not applied to the single Trp 
mutants of UCP2 which may have elucidated the relative importance of one Trp 
residue (W176 or W283) versus the other in the   mechanism of proton transport by 
UCPs. 
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6 CONCLUSIONS AND FUTURE DIRECTIONS 
 Three selective Trp mutants of UCP2 have been produced, cloned into the 
membrane-targeting expression vector pET26b(+) and then transformed into E.coli 
BL21 CD+ cells. The results of fluorescence spectroscopy based assay on the 
selective Trp mutants showed an unexpectedly high fluorescence signal when 
excited at 295nm that was insensitive to SDS denaturation but quenched by 
acrylamide, which is normally a specific quencher of Trp fluorescence in proteins. 
These results suggest significant contamination with one or more other proteins 
persists after isolation by differential centrifugation and purification by IMAC. The 
possible reasons leading to this contamination were discussed in section 5.2. In 
order to definitively establish the presence or absence of Trp in the W176Y-W283F 
samples the next goal of this project would be to perform Trp amino acid analysis on 
the purified stocks of each of the selective Trp mutants of UCP2 using the procedure 
outlined in [61]. If Trp is not detected in the W176Y-W283F samples then this 
would suggest that the fluorescence observed is either due to another fluorophore 
present in UCP2 such as a tyrosinate residue or some specific interaction of side 
chains that occurs in UCP2. Finally, it was observed that the W176Y-W283F UCP2 
mutant had an almost 25% decrease in specific proton transport rate relative to the 
wt protein, suggesting that the two conserved Trp residues found in all human UCPs 
play a role in mediating the proton transport activity of these proteins.  In 
conclusion, the results of this study seem to suggest that the purification system 
developed for purifying UCP2 from the membrane-targeted bacterial expression 
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system does not yield UCP2 at a sufficient degree of purity, contrary to the initial 
assessment.  If this is indeed the case, the problem may be mitigated by modifying 
the imidazole concentrations used in the IMAC buffers, or if this proves insufficient, 
by replacing the His-tag with a strep-tag and running on a strep-tactin column [70].  
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M.Sc. Thesis Appendix 
Appendix 1: Full Primer List for PCR 
 Forward Primer Reverse Primer 
UCP2 
Flanking 
Primers 
 
5’GGAGATATACCCATGGGAGGATCGCATCACC’3 
 
5’CGCAAGCTTGTCGACGGAGCTCTTAGAAGGG’3 
NcoI 
Removal 
Primers 
 
5’-GCACCATTCTGACTATGGTGCGTACTGAGG-3’ 
 
5’-CCTCAGTACGCACCATAGTCAGAATGGTGC-3’ 
W176Y 
Primers 
 
5’GGGTTCCGGGGCCTCTACAAAGGGACCTCTCCC’3 
 
5’GGGAGAGGTCCCTTTGTAGAGGCCCCGGAACCC’3 
W283F 
Primers 
 
5’ CTCCGCTTGGGTTCCTTCAACGTGGTGATGTTC 3’ 
 
5’GAACATCACCACGTTGAAGGAACCCAAGCGGAG’3  
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Appendix 2: Sequencing Results 
 
 
W176Y Forward Sequencing with T7 Primer 
  101 
 
 
W283F Reverse Sequencing with T7 Terminator Primer 
 
 
